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ABSTRACT 
 
 
 NK cell transplantation has been increasingly used to treat cancers that are 
resistant to chemotherapy. However, not all cancers are susceptible to NK cell killing. 
The prevalence and mechanisms of NK cell resistance have not been well elucidated. 
Because NKG2D is a major activating receptor on NK cells, we sought to test the 
hypothesis that NKG2D is the primary pathway in tumor cell recognition. Herein, we 
comprehensively assessed 20 cancer cell lines representing a broad array of cancer types. 
In line with our primary hypothesis, no cancer cell lines that expressed low levels of 
NKG2D ligands were susceptible to NK cell lysis. Furthermore, we found that only 30% 
of the cancer cell lines were susceptible to NK cell killing and all of them expressed high 
level of NKG2D ligands. The dependency on NKG2D pathway in these NK susceptible 
cells was confirmed by anti-NKG2D antibody blocking experiments. For the 70% of cell 
lines that were resistant to NK cells, 65% were due to silencing of NKG2D ligand 
expression, whereas 35% were due to insufficient NKG2D activation. For the former cell 
lines, NKG2D ligand expression was found to be downregulated at the mRNA or protein 
level. By histone acetylation or proteasome modulation, these regulatory checkpoints 
could be circumvented to obtain sufficient surface expression of NKG2D ligands to 
overcome NK resistance. For the latter cancer cell lines that were NK resistant despite 
high NKG2D ligand expression, KIR inhibition was found to override NKG2D activation 
in 80% of these cancers. MHC blockade successfully increased NK susceptibility of these 
cell lines. In the remaining 20%, downregulation of ICAM-1 was responsible for NK 
resistance. In conclusion, we successfully obtained sufficient evidence to support our 
hypothesis that NKG2D is the primary pathway for tumor cell recognition. Evasion of the 
NKG2D pathway is common through NKG2D ligand silencing, KIR inhibition, or 
inadequate expression of adhesion molecules to mediate immune-synapse formation. 
Because these resistance mechanisms are readily amenable to therapeutic alteration, NK 
cell transplantation holds promise for future cancer therapy. 
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CHAPTER 1.    INTRODUCTION 
 
 
Immunobiology of NK Cells 
 
 The first documented description of natural killer (NK) cells dates back to 1975 
when Rolf Kiessling described a unique subset of large granular lymphocytes that can 
directly lyse tumor cells without prior sensitization. Kiessling isolated and characterized 
these cells and named them natural killer due to their ‘natural’ occurrence and ability to 
kill tumor cells [1, 2]. In humans, NK cells are the third largest lymphocyte population 
comprising of 5-10% of peripheral blood lymphocytes. They are derived from CD34+ 
hematopoietic progenitor cells [3] in the bone marrow and are relatively short lived 
(approximately 2 weeks) [4]. NK cells are phenotypically characterized by the surface 
expression CD56 and the absence of CD3 (CD56+ CD3-) [5]. Furthermore, human NK 
cells can be divided into two functional subsets based on their surface expression of 
CD56: CD56bright immunoregulatory cells and CD56dim cytotoxic cells [6]. Around 90% 
of peripheral blood and spleen NK cells are CD56dim and express perforin. These cells are 
cytotoxic through granzyme degranulation. In contrast, CD56bright cells lack perforin and 
are predominant in the lymph nodes and tonsils. These cells readily produce IFN-γ in 
response to stimulation with interleukin (IL)-12, 15 and 18 [7, 8]. 
 
 
Effector functions of NK cells 
 
Cytotoxicity 
 
 Natural cytotoxicity of NK cells is mediated via perforin/granzyme pathway or 
the death receptor pathway. Perforin/granzyme-mediated apoptosis is the principal 
pathway used by NK cells to eliminate virus-infected or tumor transformed target cells 
[9]. Studies in perforin-deficient mice have revealed that this protein is required for most 
NK cell cytotoxicity [10]. After effector–tumor-cell interaction (conjugation), cytotoxic 
granules become re-oriented towards the tumor cell, and their contents are secreted into 
the intercellular cleft between effector and tumor cells in a calcium-dependent manner. 
These granules contain perforin, which disturbs the tumor-cell membrane and allows the 
entry of serine proteases known as granzymes [9]. The two most-abundant granzymes, A 
and B, have been implicated in mediating apoptosis of target cells through caspase-
dependent and -independent pathways [11]. Furthermore, NK cells can also induce 
apoptosis of their targets via death receptor pathways [12]. Some NK cells express FAS 
ligand (FASL) or tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL). 
These bind to and activate their receptors, FAS and TRAIL receptor (TRAILR), 
respectively, which are expressed by some tumor cells inducing tumor cell apoptosis [13, 
14]. 
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Cytokine production 
 
 NK cells are major producers of IFN-γ in physiological and pathological 
conditions [15]. They also produce both proinflammatory and immunosuppressive 
cytokines such as tumor necrosis factor-α (TNF-α) and IL-10 respectively. By production 
of cytokines, NK cells can act as regulatory cells to influence various cell types such as T 
cells, B cells and dendritic cells (DCs). NK cell derived IFN-γ and TNF-α helps NK cells 
cross talk with DCs in many ways including NK cell killing of immature DC and the 
promotion of DC maturation which leads to enhanced antigen presentation to T cells [16]. 
Production of IFN-γ by NK cells helps shape T cell responses in lymph nodes, possibly 
by a direct interaction between naive T cells and NK cells migrating to secondary 
lymphoid compartments from inflamed peripheral tissues [17, 18]. Furthermore, NK cells 
also secrete many chemokines that is key to their colocalisation with other hematopoietic 
cells such as DCs in areas of inflammation [19]. 
 
 
Regulation of effector functions 
 
 NK cells can distinguish between healthy cells and abnormal cells by using a 
sophisticated repertoire of cell surface receptors that control their activation, proliferation 
and effector functions. The activating receptors stimulate NK cell activity while the 
inhibitory receptors dampen NK cell responses. Regulation of NK cell function was 
initially explained by the “missing-self” hypothesis proposed by Karre et al. Their 
seminal study in 1986 noted that NK cells appear to be actively inhibited from 
responding when they encounter certain tumor cells that express MHC class I [20]. 
Because MHC class I molecules are expressed by all nucleated cells, they are an ideal 
universal marker of healthy self. The ability of NK cells to lyse cells ‘missing-self’ 
predicted the existence of inhibitory receptors and revealed a mechanism whereby NK 
cells provided immune surveillance for cells that had downregulated MHC class I, a 
frequent event in cellular transformation or virus infection to avoid recognition by CD8+ 
T cells [21, 22] (Figure 1-1). However, missing from the ‘missing-self’ hypothesis was 
any molecular basis of how NK cells are activated when they encounter tumor or virus 
infected cells or how NK cells efficiently lyse target cells that have an intact MHC class I 
surface expression. 
 
 Discovery of activating receptors on NK cells, led to the ‘dynamic equilibrium’ or 
‘rheostat’ concept- a contemporary modification of the ‘missing-self’ hypothesis [23] 
(Figure 1-2). According to this concept, NK cells sense the density of various surface 
molecules expressed on the target cells [24]. The integration of these distinct signals 
dictates the quality and the intensity of the NK cell response. In essence, inhibitory 
receptors serve as a rheostat, regulating and dampening activating signals, rather than 
completely terminating them. When NK cells and target cells interact, the information is 
interpreted by an analog and not a binary process. Thus, when an NK cell encounters a 
target cell with no inhibitory or activating ligand, there is no target cell lysis by the NK 
cell (Figure 1-2A). If the target cell expresses the inhibitory MHC class I but no 
activating ligands, NK cells do not lyse the target cells due to the existence of   
 3 
 
 
 
Figure 1-1. Regulation of NK cell function according to the 'missing-self' 
hypothesis. 
(A) Normal cells expressing self MHC class I molecules engage inhibitory receptors on 
NK cells. Recognition of self MHC class I spares normal cells from NK lysis. (B) If the 
target cell loses expression of MHC class I molecules, owing to viral infection or 
transformation, then the MHC-binding inhibitory receptor at the surface of the NK cell is 
not engaged. Thus, the NK cell does not receive inhibitory signals and therefore lyses the 
target cell. In this case, the target cell is perceived by the NK cell to be ‘missing self’. 
  
A 
B 
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Figure 1-2. Regulation of NK cell function as explained by the dynamic 
equilibrium concept. 
Depiction of possible outcomes of encounters between NK cells and target cells. 
  
A 
B 
C 
D 
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inhibitory signals (Figure 1-2B). When the target cells express activating but no 
inhibitory ligands, NK cells lyse the target cells (Figure 1-2C). However, in the presence 
of both activating and inhibitory signals, the outcome is determined by summation of 
strength of the signals (Figure 1-2D). The amount of activating and inhibitory receptors 
on the NK cells, the amount of ligands on the target cells as well as the qualitative 
differences in the signals transduced determine the extent of NK response. The failure of 
NK cells to lyse target cells can be either due to active inhibition or alternatively due to 
the absence of sufficient activation. In experimental models, when multiple activating 
receptors are engaged simultaneously [25] or when a sufficiently potent NK activating 
receptor is stimulated [26, 27], NK cells are capable of lysing target cells even in the 
presence of inhibitory signaling through ligation of inhibitory receptors and MHC class I 
molecules. In summary, the dynamic regulation of NK cell effector functions proposes 
that the balance of signals from inhibitory and activating receptors together dictate the 
fate of the target (Figure 1-3). 
 
 Lysis of target cells by NK cells involves 3 sequential steps, each of which are 
under tight regulation. First, NK cells adhere to target cells resulting in the formation of 
immune-synapse. This is followed by NK cell activation by integration of signals from 
the activating and inhibitory receptors and finally granule exocytosis resulting in target 
cell death (Figure 1-4). The NK cell detection system includes a variety of cell surface 
adhesion receptors, activating receptors and inhibitory receptors, the engagement of 
which regulates NK cell activities. Conjugate formation between NK effectors and target 
cells is a prerequisite for cytotoxicity, and is primarily mediated by binding of the NK 
surface adhesion molecules LFA-1 (CD1la/CDl8) and CD2 to their respective target cell 
ligands, intracellular adhesion molecule-1 (CD54) and LFA-3 (CD58) [28]. In humans, 
the MHC class I specific inhibitory receptors include the killer cell immunoglobulin-like 
receptors (KIRs) and the lectin–like CD94-NKG2A heterodimers [29]. These inhibitory 
receptors carry in their cytoplasmic tails immunoreceptor tyrosine based inhibition motifs 
(ITIMs), which become phosphorylated upon receptor engagement and recruit tyrosine 
phosphatases SHP-1 and SHP-2. These tyrosine phosphatases suppress NK cell responses 
by dephosphorylating protein substrates of the tyrosine kinases linked to the activating 
NK cell receptors. Activating receptors on human NK cells include the FcγRIIIA (CD16) 
receptor involved in antibody-dependent cell cytotoxicity (ADCC) [30], the natural 
cytotoxicity receptors (NCRs) including NKp46 [31], NKp44 [32], NKp30 [33] and the C 
type lectin-like superfamily member NKG2D [34]. Some of these activating receptors 
contain immunoreceptor tyrosine based activation motifs (ITAMs) in their cytoplasmic 
domains and some mediate signals through adaptor proteins like DNAX activating 
protein of 10kDa (DAP10). In addition, NK cells also express co-receptors that cannot 
directly mediate lysis of target cells but play an important role in reinforcing the strength 
of activating signals [35]. These include the receptors 2B4 [36], NTB-A [37], DNAM-1 
[38] and NKp80 [39].  
 
 Both ITAM-dependent signaling and DAP10-dependent signaling of NK 
activating receptors converge on a common NK cell cytotoxicity pathway. This common 
pathway involves the activation of Rac, which sequentially leads to activation of the  
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Figure 1-3. Outcome of NK cell response is dependent on the balance between 
activating and inhibitory signals. 
According to the ‘dynamic equilibrium’ concept, the balance of activating and inhibitory 
signals ultimately decides the fate of the target cell. 
  
 7 
 
 
Figure 1-4. Sequential steps involved in the NK lysis of target cells. 
Three steps involved in the lysis of target cells by NK cells. 1) Adhesion mediated by the 
adhesion receptors and ligands results in the formation of immunosynapse. 2) 
Engagement of activation and inhibitory receptors with their respective ligands, 
integration of signals and NK cell activation. 3) The activated NK cell undergoes granule 
exocytosis resulting in target cell death. 
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mitogen activated protein kinase (MAPK), extracellular signal regulated kinase (ERK) 
and mitogen activated or extracellular signal regulated protein kinase kinase (MEK) [40] 
resulting in the redistribution of intracytoplasmic granules and their release. Thus 
signaling by co-receptors like DNAM-1 (ITAM-dependent) can provide a synergistic 
signal to NKG2D signaling which is mediated through DAP10. 
 
 Inhibition by ITIM bearing inhibitory receptors of activating signaling is saturable 
and proportional to the magnitude of engagement of both types of receptors by their 
cognate ligands. When ITIM bearing receptors engage their ligands, the tyrosine residue 
is phosphorylated, probably by a Src family kinase, resulting in the recruitment of the 
lipid phosphatase SHIP-1or the tyrosine phosphatases SHP-1 or SHP-2 [41]. The 
inhibitory NK receptors recruit these phosphatases to the interface between the NK cell 
and its prospective target cell, and these tyrosine phosphatases suppress NK cell 
responses by dephosphorylating the protein substrates of the tyrosine kinases linked to 
activating NK receptors.  
 
 Inhibitory and activating receptors act in concert and co-aggregation between 
activating and inhibitory receptors is required for inhibition to occur [42]. A dynamic 
equilibrium is set between the “strength” of activating and inhibitory signals and is 
relayed by the level of tyrosine phosphorylation of critical signaling components (like 
Vav1) that can serve as targets for both Syk-family protein tyrosine kinase and SHP-1 or 
SHP-2 protein phosphatases [43]. 
 
 In our study, we focused on the NKG2D pathway because unlike NCRs that are 
expressed at different surface densities in different NK cells, the expression of NKG2D is 
relatively homogeneous [44]. Both NCR bright and NCR dull NK clones show comparable 
surface densities of NKG2D [45, 46]. Also till date, tumor ligands for the NCRs remain 
undefined except for B7-H6 which has been recently identified as a ligand for NKp30 
[47].  
 9 
The NKG2D Pathway 
 
 Natural Killer Group 2 member D (NKG2D) was identified in a screen for genes 
that are preferentially expressed by human NK cells [48, 49]. Interest in NKG2D was 
prompted by a curiosity in identifying activating receptors used by NK cells to recognize 
target cells. In humans, NKG2D is expressed on NK cells, CD8+ T cells and γδ T cells 
[34, 50, 51]. NKG2D is encoded by a gene on human chromosome 12 mapping within 
the natural killer (NK) gene complex. This receptor belongs to the type II C-type lectin 
like family of transmembrane proteins [52]. In humans, NKG2D is expressed as a 
homodimer in association with its adaptor molecule DNAX activating protein of 10kDa 
(DAP10) [53] (Figure 1-5). Each NKG2D homodimer assembles on the cell surface with 
two dimers of DAP10, thereby forming a hexameric structure, which reduces the 
threshold of ligand levels required for inducing signal transduction [54]. The association 
of NKG2D with DAP10 is necessary for signaling and considered important for its cell 
surface expression. DAP10 is a type I transmembrane protein with conserved aspartic 
acid residues in its transmembrane region that interacts with a positively charged arginine 
residue in the transmembrane region of NKG2D [55]. Engagement of NKG2D in human 
NK cells results in tyrosine phosphorylation of DAP10 and coupling of the receptor to the 
phosphatidylinositol-3-kinase (PI3K)/ growth factor receptor bound protein 2 (Grb2)-Vav 
pathway [56]. The PI3K pathway plays a critical role in regulating NK cytotoxicity by 
promoting perforin and granzyme B movement toward target cells and DAP10-mediated 
cytokine production [40, 57]. 
 
 NKG2D ligands are diverse proteins that are structurally similar to MHC class I 
molecules (Figure 1-5). In humans, NKG2D ligands fall into two families- the MHC 
class I chain related gene A (MICA) and B (MICB) family and the cytomegalovirus UL-
16 binding protein (ULBP) family comprising of ULBP1-ULBP3 proteins. First evidence 
of a protein that binds to NKG2D came from studies showing that a soluble form of 
MICA binds to various lymphocyte subsets. A monoclonal antibody blocking the 
interaction was subsequently shown to bind NKG2D [34]. Further analysis showed that 
MICB- a close relative of MICA (84% identical) also binds NKG2D [58]. No functional 
homologues of MICA and MICB are present in mice. MICs are highly glycosylated 
transmembrane proteins possessing the characteristic MHC class I like α1, α2 and α3 
domains [59, 60]. Despite the presence of the α3 domains, MICA and MICB do not 
associate with β2 microglobulin or require β2 microglobulin for their surface expression. 
MICs are highly polymorphic with more than 50 MICA and 13 MICB alleles so far 
reported [61].  
 
 A distinct approach identified three related human proteins that bind to the UL16 
protein of human cytomegalovirus (HCMV). UL16 was studied because it was a 
candidate virus protein involved in immune escape. ULBP1 was first identified on the 
basis of its binding to the HCMV glycoprotein UL16. Subsequent database searches for 
homologues of ULBP1 led to the identification of additional ULBP members. ULBPs 
also contain α1 and α2 domains but lack the α3 domain and are expressed as 
glycosylphosphatidylinositol (GPI) anchored proteins [62, 63]. Notably, the MICs and 
ULBPs only share 20-25% sequence homology [64].  
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Figure 1-5. NKG2D receptor and ligands in humans. 
Illustration of the human NKG2D receptor and its ligands. Also depicted is the classical 
MHC class I molecules.  
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 Given that the NKG2D ligands vary in structure and sequence, it is pertinent to 
wonder whether all ligands are equally able to bind to NKG2D and invoke an activating 
signal in immune cells. The binding of NKG2D to its various ligands is generally of high 
affinity than many immunoreceptor ligand interactions [65]. Three dimensional structure 
analyses indicate that ligand binding to NKG2D is focused on key tyrosine residues that 
are rigidly held in the NKG2D structure. Crystal structure studies of human NKG2D in 
complex with MICA and ULBP3 reveal that NKG2D binds to the α1/α2 helices of the 
ligands. Notably, most of the receptor amino acid residues that dominate binding to 
different ligands are the same and several of the contact residues between different 
ligands are conserved, especially those that contribute most of the binding energy. 
Therefore, despite differences in the amino acid sequences of different NKG2D ligands, 
they interact with the receptor similarly, and the receptor does not seem to undergo 
marked conformational changes (induced fit) to accommodate different ligands. Rather 
binding of NKG2D with diverse ligands is explained as ‘rigid adaptation’, in which a 
rigid binding site on NKG2D makes diverse interactions with a series of structurally 
distinct ligand surfaces by utilizing a core set of residues capable of multifarious bonds 
[66]. Binding studies of human NKG2D with MICA reveal that each NKG2D 
homodimer can only bind with a single monomeric ligand suggesting that NKG2D can 
bind to only one ligand at a time. [67, 68].  
 
 The NKG2D ligands are encoded by genes in the hosts’ own genome i.e. they are 
self proteins as opposed to foreign antigens. Moreover, they are either absent or present at 
low levels on normal healthy cells but their expression is often upregulated in 
pathological conditions like infection or tumor transformation. Therefore recognition of 
NKG2D ligands by NKG2D is referred to as ‘induced-self’ recognition. Although 
NKG2D ligands are often upregulated as a result of cellular stress, infection or 
tumorigenesis, the mechanisms that regulate their expression are still ill-defined. Several 
studies indicate that the regulation of individual NKG2D ligands differs substantially in 
particular tumors or infected cells, suggesting that the diverse NKG2D ligands do not 
simply reflect the redundant expression of molecules with the same function.  
 
 The first insight into the regulation of NKG2D ligands came from analysis of the 
promoters of MICA and MICB, which were found to resemble the promoter of heat 
shock protein (HSP)70 [69]. Accordingly, expression of MICA is induced by heat shock 
[59]. On the basis of sequence analysis, investigators have shown that heat shock 
elements may also exist in some ULBP genes but it hasn’t been demonstrated that these 
genes are regulated by heat shock [70]. It has also been proposed that NF-κB may 
stimulate MICA transcription and an NF-κB binding site in intron 1 of the MICA gene 
has been described [71, 72]. Studies of MICA, MICB and ULBP1 genes have identified 
potential binding sites for Sp family transcription factors [69, 73]. In addition, the DNA 
damage pathway has also been implicated in induction of NKG2D ligands [74, 75]. DNA 
damaging agents activate ATM and ATR thereby activating the DNA damage response 
resulting in ligand induction. Thus, DNA damage response, which arrests the cell cycle 
and enhances DNA repair functions, or triggers apoptosis, also alerts the immune system 
in response to potentially dangerous cells through the activation of NKG2D. However, 
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the mechanism of regulation of NKG2D ligands by the DNA damage response still 
remains poorly understood [76]. 
 
 There are also some reports of micro RNA mediated regulation of NKG2D ligand 
expression. Initially, HCMV and other virus encoded micro RNA’s were shown to 
downregulate expression of MICA, MICB or ULBP3 [77-79]. However, subsequently 
Stern-Ginossar et al showed that certain cellular micro RNA’s can also target the MIC 
transcripts. They reported that cellular micro RNAs maintain threshold levels of MICA 
and MICB in normal cells while transcriptional induction of the ligand genes can 
overcome this buffering capacity of micro RNAs [80]. Some studies on post translational 
regulation of NKG2D ligands have also been reported but primarily in the mouse system. 
Nice et al reported that the mouse NKG2D ligand MULT1 is polyubiquitinated and 
degraded in unstressed cells while in cells subjected to heat shock or UV irradiation 
MULT1 was less ubiquitinated and expressed on the cell surface [81, 82]. Although there 
is no direct evidence yet of such regulation of human NKG2D ligands, the intracellular 
sequestration of MICA in melanoma cells may perhaps be due to a similar or related 
mechanism [83]. Post translational regulation of MICs has been reported in the context of 
viral infections. Kaposi’s sarcoma-associated herpesvirus (KSHV) encoded E3 ubiquitin 
ligase K5 can downregulate cell surface MICA and MICB. However, unlike MULT1, 
ubiquitination of MICA resulted in redistribution of MICA from the plasma membrane 
but not its degradation [84].  
 
 One of the most important findings in NKG2D ligand regulation is that ligands 
are proteolytically cleaved from the cell surface or excreted in exosomes. Soluble forms 
of MICs and ULBPs have been observed in cancer patients and cancer cell culture 
supernatants [85-90]. The presence of soluble ligands may act as indicators of poor 
prognosis in cancer patients [91]. Shedding of ligands was shown to be due to cleavage of 
extracellular domain of NKG2D ligands by matrix metalloproteinases (MMPs) [86, 89]. 
Also, the membrane associated disulphide isomerase endoplasmic reticulum protein 5 
(ERP5) was shown to be responsible for proteolytic shedding of MICA [92]. In one 
study, ULBP3 in tumor cell culture supernatants was associated with exosomes while 
ULBP2 was primarily in the cleaved form [93]. Shedding of NKG2D ligands can result 
in lowered NK susceptibility of tumor cells due to lower surface expression of the ligands 
[90]. Although, some studies also report downmodulation of the NKG2D receptor in the 
presence of soluble ligands [85, 93], some others propose contrasting observations [89, 
94, 95]. Taken together, although there is some understanding of how NKG2D ligands 
are regulated, a lot is still unknown. Increased knowledge of the differential expression 
and regulation of NKG2D ligands will contribute to our understanding of tumor 
immunosurveillance and help in therapeutic interventions that induce NKG2D mediated 
immune responses. 
 
 The NKG2D system has evolved to function as a sensory system to alert the 
immune system in response to infections and tumors. Initially, Bauer et al reported that 
target cells ectopically expressing NKG2D ligands are efficiently eliminated by NKG2D 
expressing immune cells [34, 96, 97]. These observations were subsequently made in 
vivo as well [26, 27]. A noteworthy observation of NKG2D in tumor immunity was 
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provided by NKG2D neutralization experimental models. When mice were injected with 
antibody to neutralize NKG2D, they showed an increased susceptibility to carcinogen 
methylcholanthrene (MCA) induced fibrosarcoma in comparison to the isotype control 
treated mice [98]. Furthermore, a critical role of NKG2D in tumor immunosurveillance in 
vivo was proposed by Guerra et al. They reported that NKG2D deficient mice when 
crossed to TRAMP mice that spontaneously develop prostrate adenocarcinoma showed a 
higher incidence of aggressively arising tumors in comparison to the control mice [99]. In 
addition to tumor surveillance, NKG2D has also been implicated in pathogen immunity 
[62].  
 
 The interesting promiscuous nature of NKG2D also deserves a mention. Most NK 
receptors bind to one or two proteins but NKG2D is a notable exception to this rule. 
Although the exact reason for ligand diversity for a conserved receptor isn’t known, there 
are several speculative theories. One of the notions is that selection pressure by viruses 
has led to the diversity in NKG2D ligands. Infection of cells by viruses particularly 
HCMV, Influenza A and Epstein Barr virus has shown to induce NKG2D ligand 
expression [100-102]. However, HCMV deploy immunoevasins that prevent the surface 
expression of NKG2D ligands and help escape NK killing. Interestingly however, each 
immunoevasin only has limited capacity to bind NKG2D ligands. For example, the 
HCMV protein UL16 can intracellularly sequester MICB, ULBP1 and ULBP2 but not 
MICA and ULBP3 [103-105]. In this scenario, having multiple NKG2D ligands is 
therefore beneficial to the host to alert its immune system to viral infection. Competition 
with viruses, thus presents an attractive theory for the presence of NKG2D ligand 
diversity. Another theory is the differential binding affinities of various ligands to 
NKG2D. Theoretically, the expression of a lower affinity ligand would not invoke a 
powerful immune response and vice versa. However, these differences have not yet been 
shown to have a functional impact on NK responses [106]. Having so many ligands with 
varying binding affinities would allow for greater flexibility in the decision of the 
effector NK cells to activate or not, depending on the activation threshold set by signals 
from the engagement of other receptors. A third theory is that malignant transformation is 
a drive for NKG2D ligand diversity. From our observations and others, expression of 
different NKG2D ligands was seen to be under the control of different cancer related 
stress response pathways [107-109]. Possessing multiple NKG2D ligands that are 
regulated differently would thus provide the host with a relatively fail-safe mechanism 
for alerting the immune system.  
 
 
Clinical Significance of NK Cells 
 
 Surgery, chemotherapy and ionizing radiation have been used for decades as 
primary treatment strategies to eliminate tumors in patients. However, the development 
of resistance to drugs or radiation has led to significant tumor relapse. Hence the past few 
decades have focused on therapies that harness the power of the immune system. Tumor 
immunotherapy using various therapeutic agents including cytokines, monoclonal 
antibodies, vaccines, adoptive cell transfers has become an attractive tool for the 
treatment of malignancies [110, 111]. Cellular therapy with NK cells is increasingly 
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gaining importance and till date a number of clinical trials have tapped the beneficial 
anti-cancer potential of NK cells. 
 
 Evidence of the anti-cancer effects of NK cells came from an 11 year follow up  
study that showed that patients with low NK cell cytotoxicity were associated with a 
greater risk of cancer [112]. Various other groups reported that high levels of tumor 
infiltrating NK cells are associated with favorable tumor outcome in cancer patients 
[113]. The greatest revelation of NK cells in tumor control was shown in the context of 
allogeneic hematopoietic stem cell transplantation (HSCT). In 2002, Ruggeri et al 
demonstrated a significant long term benefit and prevention of leukemia relapse for 
haploidentical mismatched transplant recipients suffering from acute myeloid leukemia ( 
AML) [114]. T cell depleted donor grafts containing alloreactive NK cells improved the 
overall survival of patients in remission by mediating an enhanced graft versus leukemia 
(GVL) effect and significantly reducing graft versus host disease (GVHD). The decrease 
in GVHD was explained by donor NK cell alloreactivity against host antigen presenting 
cells (dendritic cells) that prevents presentation of host antigens to donor graft T cells 
[115, 116]. In addition, non-transformed tissues generally do not express ligands for NK 
activating receptors, hence alloreactive NK cells do not cause GVHD [117]. 
 
 Outside the context of allogeneic HSCT, infusion of allogeneic NK cells has also 
been explored as a means of cancer therapy. Several protocols of clinical grade NK cells 
purification and expansion are now validated and studies have shown that the infusion of 
NK cells is safe in humans [118-124]. However, no firm conclusions can be made 
regarding the clinical benefits of these NK cell infusions as the clinical efficacy of these 
NK therapies has been modest [125]. Nevertheless available data indicate that NK 
infusions are safe and can generate anti-tumor responses and long term remission in some 
patients. NK cells also express CD16 on their surface which enables them to recognize 
antibody coated target cells and trigger NK mediated ADCC. Strong evidence supporting 
role for NK mediated ADCC comes from anti-CD20 (Rituximab) treated non-Hodgkin’s 
lymphoma patients and anti-HER2 (Trastuzumab/Herceptin) treated metastatic breast 
cancer and gastric carcinoma patients [126-129]. Additionally, potential use of NK cell 
lines as a source of therapeutic allogeneic NK cells has also been reported. NK92 cells 
have been demonstrated to be safe and with potentially beneficial anti-tumor effects. It 
has received FDA approval for testing in patients with advanced malignant melanoma 
and renal cell carcinoma and is currently the only NK cell line that has entered clinical 
trials [130-133]. 
 
 In addition, genetically modified NK cells expressing chimeric antigen receptors 
(CARs) has also been reported by various groups. Successful expression of CARs against 
CEA, CD33, CD20, and Her2/neu has been shown in the context of NK cell lines where 
they improved NK responses in vitro and in vivo [134-137]. Similar observations have 
been reported with primary NK cells as well [138, 139]. Imai et al successfully 
demonstrated that NK cells from B-ALL patients genetically modified to express CD19-
CAR efficiently killed autologous leukemic cells [140].  
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 A proliferation of studies is currently exploiting the immunotherapeutic potential 
of NK cells for cancer treatment. Although the results of these NK based 
immunotherapeutic strategies to date are promising in experimental systems, their clinical 
efficacy in humans has been modest, presumably due to tumor escape mechanisms. With 
a greater understanding of NK cell recognition of target cells, treatment strategies are 
now being focused on modulation of NK cell receptors systems. NKG2D, being a major 
activating receptor on NK cells has been studied in the clinical setting as well. The 
importance of NKG2D has come from correlative observations of impaired NKG2D 
function with disease stages in cancer patients. For example, Wu et al reported that 
defective NKG2D mediated NK function correlated with cancer stages in prostate cancer 
patients [141]. Similar observations were made in multiple myeloma, colon cancer and 
glioma patients as well [88, 142, 143]. In a clinical trial involving vaccination with 
irradiated, granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting tumor 
cells and antibody blockade of cytotoxic T lymphocyte-associated antigen 4 (anti CTLA-
4) for melanoma therapy, patients who generated anti-MICA antibodies during the 
therapy showed significantly better clinical outcomes than those who did not [144]. The 
beneficial effect was shown to act through antibody antagonizing soluble MICA induced 
suppression of NK and CD8 T cell responses.  
 
 In addition, a new and interesting mechanism to utilize the NKG2D mediated 
immunity in tumor therapy has been reported. This strategy involves expression of 
NKG2D-CAR on T cells or NK cells for adoptive cell therapy. The chimeric NKG2D is 
not downregulated by soluble NKG2D ligands and can also overcome inhibitory 
signaling. This approach has been demonstrated to be very effective in various 
experimental models [145-149]. NKG2D-CAR engineered T cells are currently in phase I 
clinical trials for the treatment of ovarian cancer patients. Recently, Chang et al reported 
the expression of NKG2D-CAR on activated NK cells and demonstrated their anti-cancer 
potential in vitro and in vivo [150]. A few therapies utilizing bispecific protein to target 
NKG2D or NKG2D ligands have also shown therapeutic potential. A ULBP2-BB4 
bispecific protein increased susceptibility of multiple myeloma cell lines to NK mediated 
cytotoxicity and enhanced the elimination of a xenograft tumor when combined with 
adoptive transfer of PBMCs [151]. It was shown that ULBP2 engaged the NKG2D 
receptor while BB4 bound CD138, which is overexpressed on multiple myeloma cells.  
 
 Collectively, NK cells as tools for immunotherapy in cancer have shown promise 
in the clinic. However, the clinical efficacy of these NK based therapies can be further 
augmented by modulating receptor pathways such as NKG2D. The ability to manipulate 
not only the balance of activating and inhibitory receptors on NK cells but also their 
cognate ligands and the NK sensitivity of tumor cells, opens new perspectives in NK cell 
based immunotherapy. Thus, further benchside research focused on understanding 
mechanisms of NKG2D mediated NK resistance is needed to get a clearer picture of the 
clinical significance of this pathway that can eventually help in designing more effective 
NK therapies. 
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CHAPTER 2.    HYPOTHESES AND AIMS 
 
 
Problem at Hand 
 
 NK transplantation is being increasingly used for the treatment of chemo-
refractory cancers. Although various clinical trials have evaluated the safety and efficacy 
of NK based cancer therapies, the results were conflicting. While the safety of NK 
therapies has been firmly established, the clinical effectiveness has been modest. One of 
the reasons for the inconsistent clinical usefulness of NK therapies might be variable NK 
evasion strategies employed by tumor cells. The success of NK therapies relies heavily 
on the NK susceptibility of cancer cells. However, till date the prevalence and 
mechanisms of NK resistance has not been well elucidated. Therefore a better 
understanding of the predominance and mechanisms of NK resistance is needed for 
designing more effective NK therapies in the future.  
 
 
Central Hypothesis 
 
 NKG2D is a major activating receptor on NK cells. Hence, in our study we 
focused on this receptor pathway and examined the NK resistance mechanisms employed 
by tumor cells. We hypothesized that NKG2D is the primary pathway for tumor cell 
recognition; thereby, susceptible tumors activate NK cell through NKG2D, whereas 
resistant tumors evade NKG2D recognition. 
 
 
Specific Aims 
 
 Aim 1- To determine the prevalence of NK cell susceptibility in cancer and the 
role of NKG2D. NK susceptibility was evaluated in a spectrum of cancer cell lines and 
the role of NKG2D in cancer was investigated by determining the surface expression of 
NKG2D ligands and their contribution to NK susceptibility. Furthermore, correlation 
studies were undertaken to test the hypothesis that NK susceptibility directly correlated 
with the level of NKG2D ligands expressed by tumor cells. 
 
 Aim 2- To identify the molecular mechanisms of NK resistance, if any. The two 
hypothetical mechanisms included a) the absence of NKG2D activation, or b) the 
presence of NKG2D activation but overridden by inhibitory signals. 
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CHAPTER 3.    MATERIALS AND METHODS 
 
 
Cancer Cell Lines 
 
 K562, U937, SEM, RS4;11, RPMI 6666, Hs 445, Daudi, HCT116, HeLa, CAL 
27, RD and 293T cells were obtained from American Type Culture Collection (ATCC). 
Jurkat, MOLT-4, HDLM-2, L-428, L-540, L-591 and MV4-11 were purchased from the 
German Resource Center for Biological Material (DSMZ, Braunschweig, Germany). The 
cell lines NB-1691 (from Dr. Peter Houghton, Center for Childhood Cancer, Nationwide 
Children's Hospital Columbus, OH) and CHLA-255 (from Dr. C. Patrick Reynolds, 
Children’s Hospital of Los Angeles, Los Angeles, CA) were established from patients 
with different metastatic sites, stages and N-myc amplification. NKL cell line was a kind 
gift from Dr. Francisco Borrego, NIAID/NIH, Rockville, MD. YT-Indy cell line was a 
generous gift from Dr. Zacharie Brahmi, Indiana University, Indianapolis, IN. All cell 
lines were cultured as recommended and passaged with no more than 3 months. Routine 
authentication was conducted by typical morphology observation. 
 
 
Cell Purification 
 
 Peripheral blood mononuclear cells (PBMC) were collected from healthy donors 
and from pediatric leukemia patients with approval from Institutional Review Board and 
written informed consent from donors, patients, or legal guardians. Briefly, the specimens 
were layered over Ficoll-Hypaque gradient (GE Healthcare, Piscataway, NJ) and 
centrifuged at 2,300 rpm for 20 minutes. The light-density fraction was collected, 
washed, and used immediately. NK cells were enriched from healthy donor PBMCs using 
an NK Cell Isolation Kit (Miltenyi, Germany) according to the manufacturer’s 
instructions. The purity of the NK cells was more than 95% in all experiments as 
determined by flow cytometry. Enriched NK cells were activated overnight with 10U/mL 
of recombinant interleukin-2 (R&D Systems, Minneapolis, MN) in all experiments unless 
indicated otherwise. 
 
 
Phenotypic Analysis by Flow Cytometry 
 
 The following antibodies (from commercial suppliers) were used for phenotypic 
analysis: phycoerythrin (PE)-conjugated anti-MICA (159227) and anti-ULBP2 (165903); 
fluorescein isothiocyanate (FITC)-conjugated anti-ULBP1 (170818) and anti-ICAM-1 
(84H10); allophycocyanin (APC)-conjugated anti-CD56 [N901(NKH-1)] and anti-MICB 
(236511); Alexa fluor 488-conjugated anti-PI-9 (7D8); phycoeryhtrin-Texas red-
conjugated anti-CD3 (UCHT1) and unconjugated anti-ULBP3 (166510). Intracellular 
staining was performed using the Cytofix/Cytoperm kit (BD Biosciences, San Jose, CA) 
according to the manufacturer’s protocol. Flow cytometry analyses were conducted with 
LSRII or Accuri C6 flow cytometers (both from BD Biosciences) and the data were 
analyzed with FlowJo V10 (Tree Star, Ashland, OR). 
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Retroviral Constructs and Transduction of Cells 
 
 Full length MICA*001 was amplified by PCR from HCT116 cell line and cloned 
into pMSCV-IRES-GFP retroviral vector (obtained from vector lab at St.Jude). Retroviral 
supernatants were generated by co-transfecting 293T cells with plasmids encoding VSV 
gag/pol and env and pMSCV retroviral constructs using Lipofectamine 2000 (Invitrogen, 
Grand Island, NY) according to the manufacturer’s protocol. After 48 hours of 
transfection, viral supernatant was harvested and used for transducing RS4;11, Daudi and 
NB-1691 cell lines by spinoculation. Virus supernatants were mixed with cell pellets and 
centrifuged at 3900 rpm for 90 mins at 32°C in the presence of 8 ug/mL polybrene 
(Sigma, St.Louis, MO). Stable cell lines were established by sorting for GFP and MICA 
double positive cells by flow cytometry. 
 
 
NK Cytotoxicity Assay by BATDA 
 
 Target cells, including those from cell lines and primary patient samples, were 
labeled with DELFIA BATDA reagent (PerkinElmer Life and Analytical Sciences, 
Waltham, MA) according to the manufacturer’s instructions. After labeling, the cells 
were washed and then co-cultured with effector cells at 20:1 ratio (effector to target) for 2 
hours at 37°C. Cell supernatants were then mixed with DELFIA Europium solution, and 
the fluorescence was measured using a Wallac Victor 2 Counter Plate Reader (both from 
Perkin Elmer Life and Analytical Sciences). Specific lysis was calculated by a formula: 
(experimental lysis count - spontaneous lysis count) / (maximum lysis count [by lysis 
buffer] - spontaneous lysis count) times 100%. In HLA inhibition experiments, target 
cells were coated with 10 ug/mL anti-pan–major histocompatibility complex (MHC; 
LEAF clone W6/32, BioLegend, San Diego, CA) antibody for 30 minutes at 37°C prior 
to co-culture with the effector cells. For NKG2D blocking assays, primary NK cells were 
coated with 20 ug/ml anti-NKG2D blocking antibody (clone 1D11, BD Biosciences) for 
30 minutes at 37°C prior to co-culture with the target cells. 
 
 
Drug Treatments 
 
 Cell lines were treated with various concentrations of histone deacetylase 
inhibitor sodium valproate (Depacon, Hikma Farmaceutica, Portugal). MICA expression 
was observed 2 days after sodium valproate treatment for all cell lines except NB-1691 
and CHLA-255 that were analyzed 4 days post treatment. For treatment with proteasome 
inhibitor Bortezomib (Velcade, Millenium Pharmaceuticals, Cambridge, MA), various 
concentrations were used and MICA was analyzed 16 hours after treatment. The 
optimum concentration for both drugs was determined by analysis of cell viability using 
trypan blue staining. 
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Quantification of MICA Transcripts by Real-Time PCR 
 
 Total RNA was isolated from cell lines before and after sodium valproate 
treatment using the RNeasy Plus kit (Qiagen, Valencia, CA). Two μg of total RNA was 
reverse transcribed using the cDNA synthesis Vilo kit (Invitrogen) according to the 
manufacturer’s protocol. Real-time PCR analysis was performed using ABI 7900HT 
sequence detection and a Fast SYBR Green PCR master mix system (Applied 
Biosystems, Foster City, CA) according to the manufacturer's specification. Samples (50 
ng of cDNA per well) were performed in duplicate in 20μl reactions with 200nM 
primers. The real-time PCR cycling conditions were 95ºC for 20 sec; 40 cycles at 95ºC 
for 1 sec and 60ºC for 20 sec; and then extension at 72ºC for 3 mins followed by a 
dissociation phase. GAPDH was used as an internal control. Primers used were MICA 
forward 5’-ACA ATG CCC CAG TCC TCC AGA-3’, MICA reverse 5’-ATT TTA GAT 
ATC GCC GTA GTT CCT-3’, GAPDH forward 5’-GCC ATC AAT GAC CCC TTC 
ATT-3’ and GAPDH reverse 5’-TTG ACG GTG CCA TGG AAT TT-3’. MICA mRNA 
expression was normalized with that of GAPDH and compared to untreated cells.  
 
 
CD107a Degranulation Assay 
 
 NK cells pretreated overnight with 10 U/mL of IL-2 were cocultured with target 
cells at a ratio of 1:2 in the presence of FITC-conjugated anti-CD107a antibody (H4A3, 
BD Biosciences). Monensin (BD Biosciences) was added to the cells 1 hour after 
coculture. After 4 hours, the cells were harvested and stained with anti-CD3 and anti-
CD56 antibodies to determine the percentage of CD107a+ NK cells by flow cytometry. 
Anti-NKG2D and anti-HLA-ABC antibodies were also used in some experiments.  
 
 
ELISA 
 
 For detection of soluble MICA (sMICA), plates were coated overnight with 
capture anti-MICA monoclonal antibody AMO1 (BamOmaB, Germany) at 2 μg/ml in 
PBS, blocked with 3% BSA for 2 hours at 37°C and washed with buffer consisting of 1X 
TBS + 0.1% Tween 20 (TBST). Afterward 100 uL of standard (recombinant human 
MICA-Fc chimera, R&D Systems) or samples (72 hour cell culture supernatants) diluted 
in 3% BSA + 0.1% TBST were added to the plates and incubated for 2 hours at room 
temperature. After incubation, plates were washed and the detection antibody BAMO3 
(BamOmaB) at 1 μg/ml in 3% BSA + 0.1% TBST was added for 2 hours at 37°C. Plates 
were then washed and anti-mouse IgG2a-HRP (SouthernBiotech, Birmingham, AL) 
diluted 1:8000 in 3% BSA + 0.1% TBST was added for 1 hour at room temperature. 
Plates were then washed and developed using the Tetramethylbenzidine Peroxidase 
Substrate System (eBioscience, San Diego, CA). The absorbance was measured at 405 
nM using a Wallac Victor 2 Counter Plate Reader. 
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Immunoprecipitation and Western Blotting 
 
 MICA immunoprecipitation was carried out using the Pierce Classic IP kit 
(Thermo Scientific, Rockford, IL) according to the manufacturer’s instructions. Lysates 
were prepared by re-suspending cell pellets in IP lysis buffer (25mM Tris-HCl, 150mM 
NaCl, 1mM EDTA, 1% NP-40, 5% glycerol, pH 7.4) with protease inhibitor (Sigma). 
Cells were lysed at 4°C for 5 min and centrifuged at 13,000 × g for 10 min. Protein 
concentrations were determined using the Pierce BCA Protein Assay Kit (Thermo 
Scientific) according to the manufacturer’s protocol. Cell lysates containing 800ug of 
protein were pre-cleared using the control agarose resin. Pre-cleared lysates were 
incubated with 6μg anti-MICA/B antibody BAMO3 (MBL International Corporation, 
Woburn, MA) or 6ug mouse IgG2a isotype control (Abcam, Cambridge, MA) at 4°C 
overnight. Immune complexes were captured using Protein A/G Plus Agarose, washed 
with IP lysis buffer and eluted in sodium dodecylsulfate gel electrophoresis (SDS-PAGE) 
sample buffer. Samples were resolved by SDS-PAGE and transferred to nitrocellulose 
membranes. Membranes were kept in blocking buffer (LI-COR, Lincoln, NE) for 1 hour 
at room temperature, incubated with goat polyclonal anti-human MICA antibody 
(AF1300) overnight at 4°C followed by IRDye 680LT conjugated donkey anti-goat IgG 
(LI-COR). Following incubation, membranes were washed and scanned at 700 nm with 
the Odyssey infrared imaging system (LI-COR). 
 
 
Immunofluorescence Confocal Microscopy 
 
 Cells were fixed in 3.7% paraformaldehyde in PBS for 15 mins and permeabilized 
in 0.1% Triton X-100 for 10 mins. After blocking in PBS with 3% BSA and 0.02% 
Triton X-100, cells were incubated with MICA antibody AMO1 (BamOmaB) diluted 
1:100 in PBS with 3% BSA for 1 hour. Unbound primary antibody was washed out by 
rinsing three times in PBS. Bound antibody was detected with AlexaFluor 594 goat anti-
mouse IgG (Molecular Probes, Grand Island, NY) diluted 1:200 in PBS with 3% BSA. 
After unbound secondary antibody was washed out by rinsing three times in PBS, cells 
were mounted on glass slides using Prolong Gold Antifade reagent with DAPI 
(Molecular Probes). For co-localization experiments, fixed and permeabilized cells were 
incubated with organelle markers diluted in blocking buffer for 1 hour after MICA 
staining. FITC labeled antibodies to EEA1 (diluted 1:100), GM130 (diluted 1:10) and 
LAMP1 (diluted 1:10) were obtained from BD Biosciences and unconjugated anti-
calnexin antibody (diluted 1:200) was obtained from Abcam. Bound calnexin antibody 
was detected by FITC-conjugated anti-rabbit IgG (Jackson Immunoresearch, West 
Grove, PA). All procedures were performed at room temperature. Images were acquired 
on a Zeiss 510 Meta multi-photon confocal microscope (Zeiss, Oberkochen, Germany). 
Analysis was performed using LSM510 META software (Zeiss). 
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Statistical Analysis 
 
In all experiments, statistical significance was calculated using student’s t-test. 
For cluster plot analysis, mean ligand expression score and mean lysis were calculated as 
below: 
 
 
Mean ligand expression score 
 
? Expression = Ligand mean fluorescence intensity (MFI) - background MFI 
? Expression mean = natural log (Mean (expression in experiment 1+ expression in 
experiment 2+ expression in experiment 3 ) +1) 
? Expression mean weight = Expression mean X weight* for each ligand  
? Mean ligand expression score = sum of Expression mean weight within a cell line 
 
*Weight was calculated as spearman correlation coefficients between each ligand 
expression and corresponding percentage of cell lysis (Table 3-1). 
 
 
Mean lysis 
 
Mean lysis = natural log (mean (lysis at experiment 1) + (lysis at experiment 2) + 
(lysis at experiment 3) +1) 
 
 After determining the mean ligand expression score and mean lysis, K-means 
clustering method was applied to the data from 20 cancer cell lines. In this algorithm, “n” 
observations are partitioned into “k” clusters in which each observation belongs to the 
cluster with the nearest mean. Mathematically, analysis of x variables presents 2x 
possibilities. Since 2 variables were analyzed, “k” was fixed at 4 in our cluster analysis. 
The 4 phenotypes hypothesized are shown in Table 3-2. 
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Table 3-1. Weight for each NKG2D ligand 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3-2. Four possible phenotypes in our cancer cell spectrum 
 
 
 
 
 
  
NKG2D ligand Weight 
MICA 0.2616643 
MICB 0.5038257 
ULBP1 0.5758988 
ULBP2 0.4181352 
ULBP3 0.1212418 
Group Level of NKG2D ligand expression NK susceptibility 
1 High High 
2 Low Low 
3 High Low 
4 Low High 
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CHAPTER 4.    RESULTS 
 
 
Heterogeneity in NK Susceptibility and NKG2D Ligand Expression in Cancer Cell 
Lines 
 
 We first sought to determine the susceptibility of cancer cell lines to NK cell 
lysis. Resting primary NK cells from 3 healthy donors were co-cultured with different 
target cancer cells in an effector:target ratio of 20:1. A clear heterogeneity was observed 
in the cancer cell susceptibility to NK cells. Only one third of the cancer cell lines were 
susceptible to NK killing (defined as specific lysis > 10%, Figure 4-1A). Leukemic cell 
lines U937, K562, and Jurkat had a high percentage of specific lysis while another 
leukemia cell line MOLT-4, lymphoma cell line L-428 and colon carcinoma cell line 
HCT116 were moderately NK sensitive. Two thirds of the cancer cell lines exhibited 
resistance to NK killing with less than 5% specific lysis. 
 
 We determined the surface expression of NKG2D ligands MICA, MICB, ULBP1, 
ULBP2 and ULBP3 on the cancer cell lines. By flow cytometry we quantified surface 
expression in terms of mean fluorescence intensity (MFI). The ligand expression was 
found to be heterogeneous in our cancer cell line spectrum (Figure 4-1B, C, D, E and F). 
For MICA, high levels of expression were observed on HeLa, RD, L-428 and K562 and 
minimal levels on the other 16 cell lines (Figure 4-1B). For MICB, high level of 
expression was observed on K562 and low levels on Jurkat, HeLa and MOLT-4cell lines 
(Figure 4-1C). For ULBP1, high expression was observed on MV4-11 and low levels on 
U937, Jurkat, K562, HCT116 and HDLM-2 (Figure 4-1D). For ULBP2, high expression 
was seen on HeLa, Jurkat, and CAL 27, and low levels on HDLM-2, HCT116, L-428, 
K562, U937 and MOLT-4 (Figure 4-1E). Lastly, for ULBP3, very high expression was 
observed on L-428, moderate expression on RD, HDLM-2, HCT116, and CAL 27, and 
low levels on K562, HeLa, L-540, MV4-11 and Daudi (Figure 4-1F). Collectively, the 
top 5 cell lines that had the highest cumulative levels of the 5 NKG2D ligands were 
K562, HeLa, Jurkat, L-428 and HCT116. 
 
 
Level of NKG2D Ligand Expression Usually (but Not Always) Correlates with NK 
Susceptibility 
 
 In order to determine whether NKG2D ligand expression is directly proportional 
to NK susceptibility of tumor cells, the correlation between the 2 parameters was 
analyzed by K-means clustering algorithm and Wilcoxon rank-sum tests. Cluster analysis 
revealed 3 phenotypic clusters (Figure 4-2). Group 1 phenotypic cluster included U937, 
K562, Jurkat, MOLT-4, HCT116 and L-428. Compatible with our hypothesis that the 
higher the level of NKG2D ligand expression, the greater the susceptibility to NK cells, 
these group 1 cancer cell lines had abundant NKG2D ligand expression and high 
susceptibility to NK cells. Also in line with the hypothesis are the group 2 cancer cells 
with low NKG2D ligand expression and low NK susceptibility. This group included the  
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Figure 4-1. Heterogeneity in NK susceptibility and NKG2D ligand expression of 
cancer cell lines. 
(A) Percentage lysis of 20 cancer cell lines by resting primary NK cells co-cultured for 2 
hr at E:T ratio of 20:1. Data represents mean lysis ± SEM from 3 independent 
experiments. Surface expression of (B) MICA, (C) MICB, (D) ULBP1, (E) ULBP2 and 
(F) ULBP3 on 20 cancer cell lines was determined by flow cytometry and expressed as 
mean fluorescence intensity (MFI). Data represents mean ± SEM of from 3 independent 
experiments. 
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Figure 4-2. Level of NKG2D ligand expression usually (but not always) correlates 
with NK susceptibility. 
(A) Cluster plot of four distinct phenotypes in the cancer cell spectrum. Level of NKG2D 
ligand expression represents mean ligand expression score as stated in materials and 
methods. Level of NK susceptibility denotes mean lysis. (B) Mean ligand expression 
score for groups 1, 2 and 3. (C) Mean percentage of lysis for groups 1, 2 and 3. Bars 
represent median values. Data are the mean ± SEM from 3 independent experiments. 
**, p<0.01, ***p<0.001 as compared with group 1. 
  
A 
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cell lines NB-1691, CHLA-255, RS4;11, SEM, L-540, L-591, Hs 445, RPMI 6666 and 
Daudi. In contrast to the above 2 groups, group 3 cell lines had an unexpected phenotype 
of low NK sensitivity despite a high NKG2D ligand expression. Group 3 included HeLa, 
MV4-11, RD, CAL 27 and HDLM-2. Notably, none of the cell lines in our cohort 
exhibited a group 4 phenotype i.e. low NKG2D ligand expression and high NK 
susceptibility, supporting our primary hypothesis that NKG2D ligand expression is 
essential (though at times insufficient) for NK cell recognition. 
 
 
NK Sensitivity of Group 1 Cells Involves the NKG2D Pathway 
 
 To validate that the high NK susceptibility of group 1 cells was due to the 
presence of NKG2D ligands on their surface, we performed NK cytotoxicity assay in the 
presence of NKG2D blocking antibody. Primary resting NK cells were incubated with 
BATDA labeled group 1 cell lines as targets in an effector: target ratio of 20:1 in the 
presence or absence of NKG2D blocking antibody. We observed a significant reduction 
in the NK lysis of group 1 cancer cells when the NKG2D receptor was blocked on NK 
cells (Figure 4-3). More than 50% loss of specific lysis was seen in the presence of the 
NKG2D blocking antibody, suggesting that the NKG2D pathway contributed 
significantly to the NK sensitivity of the group 1 cancer cells. 
 
 
Pediatric Leukemia Patients Show a Group 2 rather than Group 1 Phenotype 
 
 Since NK transplantation is commonly used for the treatment of childhood 
leukemia, we hypothesized that pediatric leukemia exhibit a group 1 phenotype. 
Surprisingly, negligible levels of surface NKG2D ligands were observed on 8 patient 
samples when compared to K562 (Figure 4-4). One of the patient samples (represented 
as ▲) showed low level of surface expression of MICA, ULBP1, ULBP2 and ULBP3 
with low % lysis. Another patient sample (represented as ○) expressed high level of 
ULBP3 on the cell surface with NK lysis almost comparable to that of K562. As 
expected, the 8 leukemia samples that did not express NKG2D ligands on their cell 
surface exhibited NK resistance. Taken together, the majority (90%) of pediatric 
leukemia patients exhibited a group 2 phenotype with NK resistance and absence of 
NKG2D ligands, and only 1 patient (10%) showed a group 1 phenotype (high NK 
susceptibility and NKG2D ligand expression). 
 
 
Ectopic Expression of MICA Overcomes NK Resistance  
 
 In order to test our hypothesis that the absence of NKG2D ligand expression was 
solely responsible for NK resistance in the group 2 cells, we ectopically expressed MICA 
on MLL cell line RS4;11, lymphoma cell line Daudi and neuroblastoma cell line NB-
1691. We created stable MICA expressing lines via retrovirus transduction and confirmed 
surface expression of MICA on the three cell lines 72 hours post transduction by flow 
with the cytometry (Figure 4-5A). Using these cells lines as targets, we performed NK  
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Figure 4-3. NK cytotoxicity of group 1 cells involves the NKG2D pathway. 
Mean percentage specific lysis of group 1 cell lines by primary resting NK cells in the 
absence (□) or presence (■) of anti-NKG2D blocking antibody. Effector and targets were 
cocultured at 20:1 ratio and lysis was evaluated by BATDA assay. Data are mean % 
specific lysis ± SEM from 3 independent experiments. *, p<0.05 when compared to 
untreated cells. 
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Figure 4-4. NKG2D ligand expression and NK susceptibility of leukemia patients. 
Surface expression of NKG2D ligands (A) MICA, (B) MICB, (C) ULBP1, (D) ULBP2 
and (E) ULBP3 on K562 (●) and leukemia patient samples (■). Each (●) represents one 
experimental data point for K562. The outliers in patient samples are represented as (▲) 
and (○). Bars represent median mean fluorescence intensity of NKG2D ligands. (F) Mean 
percentage lysis of K562 and patient blasts by NKL cell line at E:T ratio 20:1. Bars 
represent median lysis. ***p<0.001. 
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Figure 4-5. Ectopic expression of MICA overcomes NK resistance in group 2 
cancer cells. 
(A) Histogram of MICA surface expression on group 2 cancer cell lines RS4;11, Daudi 
and NB-1691 stably transduced with empty vector (black line) or full length MICA (red 
line). Isotope control was presented as shaded histograms. (B) Cytotoxicity of NKL cell 
line against MICA transduced cell lines (■) and empty vector transduced cell lines (○). 
Data represents mean % lysis ± SEM from 3 independent experiments. *, p<0.05 
compared to cell line transduced with empty vector. 
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cytotoxicity assays using the NKG2D dependent effector cell line NKL. NK cytotoxicity 
assays revealed a significantly higher lysis of the MICA expressing cell lines when 
compared to the vector alone controls (Figure 4-5B).  
 
 
 Low Levels of MICA Surface Expression in Group 2 Cancer Cells Were in Part due 
to Transcription Silencing 
 
 To understand the mechanism of low MICA surface expression in group 2 cancer 
cells, we determined the mRNA levels by real time PCR. We found significantly lower 
levels of MICA transcripts in the group 2 cell lines when compared to group 1 cell line 
K562 (Figure 4-6). Notably, the neuroblastoma cell lines NB-1691 and CHLA-255 had 
no detectable MICA mRNA. Among the group 2 cancer cell lines, lymphoma line L-591 
had the highest levels of mRNA transcripts, compatible with the highest surface protein 
expression among this group of cell lines.  
 
 
Histone Deacetylase Inhibitors Can Upregulate MICA mRNA and Surface 
Expression in Neuroblastoma Cell Lines 
 
 Epigenetic mechanisms like histone deacetylation have been implicated in 
repression of gene transcription [152]. Altered histone deacetylase (HDAC) activity has 
been identified in several cancers [153, 154]. Hence, we investigated whether histone 
deacetylation was responsible for the low levels of MICA mRNA in the group 2 cancer 
cell lines. We observed a significant upregulation in MICA mRNA in the neuroblastoma 
cell lines NB-1691 and CHLA-255 post treatment with histone deacetylase inhibitor 
(HDACi) sodium valproate (Figure 4-7A). Flow cytometry showed a corresponding 
increase in MICA expression on the neuroblastoma cell lines (Figure 4-7B). To 
investigate NK susceptibility of the HDACi treated cells, we performed NK cytotoxicity 
assay on NB-1691 cells four days post treatment with 5mM sodium valproate. HDACi 
treated NB-1691 cells showed significantly higher NK lysis as compared to the untreated 
cells. The increase in NK susceptibility was completely abolished in the presence of anti-
NKG2D blocking antibody (Figure 4-7C). 
 
 
Histone Deacetylase Inhibitor Treatment Only Marginally Upregulated MICA 
mRNA and Surface Protein in the Leukemia and Lymphoma Group 2 Cancer Cells 
 
 For the resistant leukemia and lymphoma cell lines in our group 2 cluster, we 
determined if HDAC inhibitor treatment could upregulate MICA expression as in 
neuroblastoma. We observed only a marginal increase in the transcript levels in most of 
the cell lines, except Hs 445 and Daudi, 48 hours after sodium valproate treatment 
(Figure 4-8A). In accordance with the mRNA increase, only Daudi and Hs 445 showed 
slight increase in surface MICA expression post HDAC inhibitor treatment while the 
remaining group 2 lines showed negligible increase (Figure 4-8B). This marginal  
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Figure 4-6. Low level of MICA transcripts in group 2 cancer cells. 
MICA mRNA expression in group 2 cancer cells (■) normalized to GAPDH and relative 
to K562 (□, taken as 1). Data are mean ±SEM from 3 independent experiments. 
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Figure 4-7. HDAC inhibitor treatment upregulates MICA mRNA and protein 
levels on neuroblastoma cell lines and increases their susceptibility to NK cells. 
(A) Relative MICA mRNA levels in untreated (white) and 5mM treated NB-1691(black) 
or 2.5mM treated CHLA-255 (black) four days after treatment. Data are mean mRNA 
expression ± SEM in treated cells compared to untreated cells from 3 independent 
experiments. (B) Histograms of surface MICA on untreated (black) and sodium valproate 
treated (red) neuroblastoma cells. Isotype control was presented as shaded histograms. 
Data are representative of 4 experiments. (C) Cytotoxicity of primary NK cells against 
untreated (white), sodium valproate treated (black) NB-1691 cells and sodium valproate 
treated NB-1691 cells in the presence of anti-NKG2D blocking antibody (grey). Data are 
mean % lysis ± SEM from 3 independent experiments. *, p<0.05; **, p<0.01; 
***p<0.001. 
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Figure 4-8. Effect of HDAC inhibitor treatment on MICA mRNA and protein 
levels in the remaining group 2 cancer cells. 
(A) Relative MICA mRNA levels in untreated (white) and sodium valproate treated 
(black) group 2 cancer cells. Data are mean MICA mRNA ±SEM in the treated cells 
compared to untreated cells from 3 independent experiments. (B) Histograms of MICA 
surface expression on untreated cells (black line) and sodium valproate treated cells (red 
line) 48 hours after treatment. Isotype control was presented as shaded histogram. Data 
are representative of 4 independent experiments. (C) Cytotoxicity of primary NK cells 
against untreated (white), sodium valproate treated (black) and sodium valproate treated 
group 2 cells cells in the presence of anti-NKG2D blocking antibody (grey). Data are 
mean % lysis ± SEM from 3 independent experiments. *, p<0.05. 
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upregulation in MICA was mirrored by a marginal upregulation in the NK lysis of the 
group 2 cancer cells (Figure 4-8C). 
 
 
Group 2 Cells Express Low Levels of Intracellular MICA  
 
 To determine whether the low mRNA quantity in group 2 leukemia and 
lymphoma lines corresponded with low levels of intracellular MICA protein, we 
determined the amount of intracellular MICA using confocal microscopy (Figure 4-9). 
As expected, the level of intracellular MICA protein was much lower in the group 2 cells 
than in the group 1 cell line K562. In K562, relatively large amount of surface and 
intracellular MICA could be visualized. 
 
 
Shedding of MICA Is Not Responsible for the Absence of Surface MICA in Group 2 
Cancer Cell Lines 
 
 Having observed low amount of intracellular and surface MICA in our group 2 
cluster, we investigated whether shedding of NKG2D ligands collaborated with 
transcription silencing [85, 93]. In all group 2 cell lines, we could not detect soluble 
MICA in the culture supernatants by ELISA (Figure 4-10). Collectively, these results 
indicate that shedding of MICA did no contribute to the low surface levels in our group 2 
cancer cell lines, but rather the mechanism is related to transcription repression. 
 
 
The Small Amount of MICA in Group 2 Cells Is Retained in the Endoplasmic 
Reticulum 
 
 With high resolution confocal microscopy we next investigated the subcellular 
localization of MICA with markers for endoplasmic reticulum (calnexin), golgi complex 
(GM130), lysosomes (LAMP1) and endosomes (EEA1). Co-localization of MICA 
(shown in red) with the ER marker calnexin (shown in green) was observed (yellow 
staining) in all group 2 cell lines including RS4;11, Hs 445 and RPMI 6666. In addition, 
co-localization of MICA with calnexin was also observed in an AML patient sample that 
was negative for cell surface expression of MICA (Figure 4-11A). Clear points of co-
localization (indicated by white arrows) were observed in a single cell image of RS4;11 
(Figure 4-11B). Confocal microscopy in RS4;11 cells with other subcellular organelle 
markers revealed no significant co-localization of MICA with the golgi complex marker 
GM130 (Figure 4-11C), early lysosome marker LAMP-1 (Figure 4-11D) and early 
endosome marker EEA1 (Figure 4-11E).  
 
 
Treatment with Proteasome Inhibitor Increases Surface Expression of MICA 
 
 With knowledge of MICA being retained in the ER, we determined whether their 
surface expression could be restored using proteasome inhibitor bortezomib. MICA 
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Figure 4-9. Presence of intracellular MICA protein in group 2 cells. 
Immunofluorescence images of differential interference contrast (DIC), DAPI (blue), 
MICA (red) and merge of the blue and red channels in group 1 cell line K562 and the 
indicated group 2 lines. Results are representative of 3 independent experiments. 
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Figure 4-10. MICA is not shed by group 2 cancer cell lines. 
Level of soluble MICA in the supernatants of group 2 cell lines. Data represent mean 
soluble MICA (pg/mL) ± SEM from 2 independent experiments. Red line represents the 
background level from medium alone control. The detection limit of the ELISA was 50 
pg/mL to 6250 pg/mL. 
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Figure 4-11. MICA is retained in the endoplasmic reticulum. 
(A) Confocal microscopy images showing co-localization of MICA (red) with ER marker 
calnexin (green) in the indicated group 2 cell lines and in a patient sample. Results are 
representative of 2 independent experiments. (B) Single cell image RS4;11 cell showed 
MICA co-localization with calnexin. White arrows show points of colocalisation. 
Confocal microscopy images showing no significant co-localization of MICA with other 
compartment markers including (C) Golgi marker GM130; (D) lysosome marker LAMP1 
and (E) early endosome marker EEA1 in RS4;11 cells. 
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Figure 4-11. (Continued). 
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immunoprecipitation revealed an increase in intracellular MICA in group 1 cell line 
HCT116 and group 2 cell lines L-591 and RS4;11, which in turn increased the surface 
expression of MICA (Figures 4-12A and B). The effect of bortezomib was independent 
of the background expression of MICA since it upregulated MICA in the group 1 
HCT116 cells that show surface MICA and also on the group 2 cells that have low to 
negligible levels of surface MICA. We further investigated whether the increase in 
surface MICA could increase NK susceptibility. NK cytotoxicity assays revealed that L-
591 cells had a significantly higher NK lysis post bortezomib treatment. To validate that 
the augmented susceptibility was due to the NKG2D pathway, we neutralized the 
receptor on NK cells using anti-NKG2D blocking antibody. When anti-NKG2D blocking 
antibody was applied, a significant reduction in NK susceptibility of L-591 cells was 
observed (Figure 4-12C). 
 
 
NK Resistance of Group 3 Cell Lines Was Not due to PI-9 Overexpression 
 
 We then investigated the mechanisms of NK resistance in the group 3 cell lines 
despite high level of NKG2D ligand expression. It is well known that tumors can resist 
cytotoxic T lymphocyte mediated killing by expression of the serine protease inhibitor 
protease inhibitor 9 (PI-9) which inactivates granzyme B [155]. Hence, we considered 
whether overexpression of protease inhibitor 9 was a possible mechanism for NK 
resistance in our group 3 cell lines. The NK resistant group 3 cancer cells showed similar 
levels of PI-9 expression as the NK sensitive group 1 cells (Figure 4-13). Positive control 
YT-Indy NK cells showed high levels of intracellular PI-9 by flow cytometry. This 
indicated that overexpression of PI-9 was not a contributing factor to the NK resistance in 
the group 3 cells. 
 
 
KIR Inhibition Overrides NKG2D Activation in Group 3 Cells 
 
 According to the rheostat concept, inhibitory signals overriding the activating 
signals can lead to NK resistance of tumors [24, 156]. To determine if this was indeed the 
mechanism of resistance in our group 3 cells, we examined the expression level of KIR 
inhibitory ligands HLA-ABC on our group 3 cell lines. All cancer cell lines showed high 
level of KIR inhibitory ligands on the cell surface (Figure 4-14A). When we performed 
NK cytotoxicity assays with primary NK cells against the group 3 lines in the absence or 
presence of anti-HLA-ABC blocking antibody, blockade of the inhibitory signals resulted 
in a significant increase in NK susceptibility of HeLa, HDLM-2, CAL 27, and MV4-11. 
When saturating amounts of the anti-NKG2D blocking antibody was applied, the 
augmented NK sensitivity was considerably reduced suggesting that the increased NK 
susceptibility was due to the activating signals from the NKG2D pathway in K562 and 
HDLM-2 (Figure 4-14B). However, RD rhabdomyosarcoma cells did not show increased 
NK sensitivity in the presence of the anti-HLA antibody. 
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Figure 4-12. Treatment with proteasome inhibitor increases surface expression of 
MICA. 
(A) MICA immunoprecipitation showing MICA levels in the absence (-) or presence (+) 
of bortezomib 16 hours after treatment in the indicated cell lines. Data are representative 
of 2 experiments. (B) Histograms of surface MICA expression in untreated cells (black 
line) and bortezomib treated cells (red line). Isotype control was presented as shaded 
histograms. Data are representative of 3 experiments. (C) NK susceptibility of untreated 
or 25nM bortezomib treated L-591 cells in the presence of isotype control (white) or anti-
NKG2D antibody (black). Data are mean % lysis ± SEM from 3 independent 
experiments. *, p<0.05; **, p<0.01.  
A 
B 
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Figure 4-13. No significant difference in PI-9 levels between group 1 and group 3 
cell lines. 
Bars represent mean PI-9 MFI in group 1 and group 3 cell lines. Data are mean MFI 
±SEM from 3 independent experiments. Positive control is YT-Indy cells. 
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Figure 4-14. KIR inhibition overrides NKG2D activation in group 3 cells. 
(A) Expression of inhibitory ligands HLA-ABC (black line) on the indicated group 3 cell 
lines. Isotype control was presented as shaded histogram. Data are representative of 2 
independent experiments. (B) NK susceptibility of group 3 cells lines untreated (blue 
line), treated with anti- HLA-ABC blocking antibody (red line), treated with anti-HLA 
blocking antibody+anti-NKG2D blocking antibody (green line) to NK cells at E:T ratios 
5:1, 10:1, 20:1. Data are mean % lysis ± SEM from 3 independent experiments. 
*, p<0.05; **, p<0.01; ***p<0.001. 
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RD Cells Cannot Degranulate NK Cells  
 
 Since blockade of KIR-HLA interaction did not augment NK sensitivity of RD 
cells, we determined whether RD cells might at least activate NK cells through NKG2D. 
We observed that the NK sensitive group 1 cell line K562 could trigger degranulation in 
42% of NK cells while the resistant group 3 lines HDLM-2 and RD could trigger 
degranulation in less than 10% of NK cells. In the presence of anti-HLA-ABC blocking 
antibody, K562 did not show an increase on CD107a+ NK cells as it lacks MHC class I 
on its surface; however HDLM-2 showed a significant increase in CD107a+ NK cells. In 
contrast, RD cells showed no increase in NK degranulation. When saturating amounts of 
anti-NKG2D antibody was applied, the percentage of CD107a+ NK cells was 
significantly reduced in K562 and HDLM-2 cell lines’ suggesting that NK activation was 
through the NKG2D pathway. No significant loss of NK degranulation was observed in 
RD cells (Figure 4-15). Taken together, these data suggested that the resistance of RD 
cells was not due to KIR-HLA inhibition, but inability to activate NKG2D despite high 
levels of NKG2D ligand expression. 
 
 
NK Resistant RD Cells Expressed Low Levels of ICAM-1 
 
 We then hypothesized that the NK resistance in RD cell line might be due to low 
levels of adhesion molecule ICAM-1, which is essential for immune-synapse formation. 
Flow cytometry revealed that ICAM-1 levels on the RD cells are indeed significantly 
lower than other group 3 cell lines (Figure 4-16). 
 
 
NKG2D Pathway Can Be Modulated in Patient Samples 
 
 We then extended our investigation from cancer cell lines to fresh patient 
samples. We carried out analyses on two representative pediatric leukemia patient 
samples. Blasts from a patient with MLL rearranged leukemia (patient 001) had low 
NKG2D ligand expression on cell surface representing group 2 cells, while those from an 
AML patient (patient 002) had high NKG2D ligand expression with low NK 
susceptibility representing group 3 cells (Figure 4-17A and E).  
 
 Based on our previous findings on the NK resistance mechanisms employed by 
group 2 cell lines, we determined whether the NKG2D ligand expression on the patient 
001 blasts could be modulated by treatment with HDACi sodium valproate and 
proteasome inhibitor bortezomib. Treatment of patient 001 blasts with sodium valproate 
or bortezomib resulted in a marked increase in the surface MICA and ULBP2 ligands 
while MICB and ULBP1 showed no change in surface expression. MICA and ULBP2 
showed a higher increase in the sodium valproate treated blasts when compared to the 
bortezomib treated blasts (Figure 4-17A and B). We observed a 2.1 fold increase in the 
percentage of degranulated (CD107+) NK cells post treatment with sodium valproate 
using the CD107 assay and a 1.4 fold increase in CD107+ NK cells post bortezomib 
treatment of the patient blasts (Figure 4-17C top panel).   
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Figure 4-15. RD cells cannot degranulate NK cells. 
Percentage of CD107a+ NK cells in the presence of target cells alone (white), target cells 
coated with anti-HLA-ABC (black), target cells coated with anti-HLA-ABC and NK cells 
coated with anti-NKG2D (grey). Data are mean percentage of CD107a+ NK cells ± SEM 
from 2 independent experiments. *, p<0.05. 
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Figure 4-16. Low ICAM-1 expression on RD cells. 
Surface expression of ICAM-1 on group 3 cell lines. Data are mean MFI ± SEM from 2 
independent experiments. 
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Figure 4-17. Modulation of NKG2D pathway in pediatric leukemia samples. 
A) Surface expression of the indicated NKG2D ligands on patient 001 blasts before 
(black line) and after 48 hour treatment with 2.5mM sodium valproate (red line). (B) 
Surface expression of the indicated NKG2D ligands on untreated patient 001 blasts 
(black line) and after 16 hour treatment with 10nM bortezomib (red line). Isotype 
controls were presented as shaded histograms. (C) NK degranulation in untreated and 
drug treated patient 001 blasts in the absence or presence of anti-NKG2D antibody 
indicated as percentage of CD107 positive cells. (D) NK susceptibility of untreated or 
drug treated patient 001 blasts at 20:1 E:T ratio in the absence (white) or presence (black) 
of anti-NKG2D antibody. (E) Surface NKG2D ligand expression on patient 002 blasts. 
(F) Susceptibility of patient 002 blasts to primary NK cells at 20:1 E:T ratio. Data are 
mean % lysis ± SEM from 3 different donors. ***p<0.001. 
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Figure 4-17. (Continued). 
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 The significant reduction in NK degranulation in the presence of blocking anti-
NKG2D antibody validated that the increase in NK activation post drug treatment was 
due to the NKG2D pathway (Figure 4-17C bottom panel). Higher NK susceptibility of 
the sodium valproate treated and bortezomib treated blasts was observed when compared 
to the untreated cells. The bortezomib treated blasts were however killed to a lesser 
extent when compared to the HDACi treated blast cells (Figure 4-17D). The percentage 
of NK degranulation and susceptibility of patient 001 blasts was in accordance with the 
level of increase in surface MICA and ULBP2 post treatment with HDACi and 
bortezomib. 
 
Blasts from patient 002 had a high NKG2D ligand expression on their surface 
(Figure 4-17E) and showed only 10% specific lysis, indicating a NK resistant group 3 
phenotype. Based on our previous observations of KIR inhibition overriding NKG2D 
activation, we treated patient 002 blasts with pan anti-HLA-ABC blocking antibody. In 
the presence of the HLA blocking antibody, a significant increase in the NK 
susceptibility of the blasts was observed. This increased NK lysis was also significantly 
diminished in the presence of the anti-NKG2D blocking antibody (Figure 4-17F). 
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CHAPTER 5.    DISCUSSION 
 
 
 Despite intensive therapy and new chemotherapeutic agents, a high incidence of 
chemo-resistance is observed in hematological malignancies and solid tumors [157, 158]. 
Investigations in the past decade have focused on inventing better immune based 
therapies, given their non-cross resistance and less overlapping side effects with current 
therapies [159, 160]. NK cell transplantation is being increasingly used for treatment of 
chemo-resistant cancers, because it has the potential to provide anticancer effects without 
GVHD or organ toxicity [161]. However, NK resistance of cancers (if prevalent) would 
undermine the efficacy of NK transplantation. In this study we showed that 1) the 
majority of cancer cell lines and pediatric patient samples are resistant to NK cell lysis, 2) 
NK resistance is commonly due to lack of NKG2D activation or due to inhibitory signals 
overriding NKG2D activation, and 3) NKG2D pathway can be modulated to overcome 
NK resistance of cancer. In addition to demonstrating that NKG2D is the primary 
pathway in NK susceptible tumors, our comprehensive study also reinforces the key 
therapeutic paradigm that the NKG2D pathway can be manipulated to increase NK 
susceptibility of tumor cells thereby improving the outcomes of NK transplantation. 
 
 
NK Resistance Is Predominant in Cancer 
 
 The occurrence of malignancies resulting via tumor escape may be due to 
defective NK cells or inherent features of tumor cells [162]. Elucidating these aspects 
regulating NK interaction with tumor cells is important to understand the role of NK cells 
in the control of cancer as well as their potential as a means of immunotherapy. Although 
various groups have investigated certain aspects of NK lysis of tumor cells [162-166], the 
prevalence and mechanism of NK resistance in cancer is still not well elucidated. In our 
study, we conducted a comprehensive analysis to determine the occurrence and frequency 
of NK resistance in cancer. Contrary to the above mentioned research groups that focused 
their study on a particular cancer type or limited number of cell lines, we analyzed NK 
susceptibility in a broad spectrum of 20 cancer cell lines representing various different 
cancer types including chronic myeloid leukemia (K562), T-cell acute lymphoblastic 
leukemia (MOLT-4, Jurkat), acute myeloid leukemia (U937), mixed lineage leukemia 
(SEM, RS4;11, MV4-11), Burkitt’s lymphoma (Daudi), Hodgkin’s lymphoma (L-540, L-
591, Hs 445, RPMI 6666, L-428, HDLM-2), colon carcinoma (HCT116), 
rhabdomyosarcoma (RD), cervical carcinoma (HeLa), head and neck squamous 
carcinoma (CAL 27) and neuroblastoma (NB-1691, CHLA-255). Our results indicate a 
very high prevalence (70%) of NK resistance with majority of the cancer cell lines 
exhibiting less than 5% specific lysis. NK resistance was not associated with any 
particular cancer type. In fact, while some leukemia lines like K562, U937, Jurkat and 
MOLT-4 exhibited high NK susceptibility some others like MV4-11, SEM and RS4;11 
showed NK resistance. Of the 6 lymphoma lines, only one cell line L-428 showed high 
NK lysis. Similarly, only one of 6 solid tumor cell lines (HCT116) was susceptible to NK 
killing. Collectively, NK resistance was commonly observed in both hematological 
malignancies and solid tumors. 
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Substantial Heterogeneity in NKG2D Ligand Expression and NK Susceptibility 
 
 We determined the surface expression of 5 NKG2D ligands on tumor cell lines 
and observed a clear heterogeneity in ligand expression. Our results show that MICB and 
ULBP1 were the least frequently expressed ligands (20-30%) while MICA, ULBP2 and 
ULBP3 were expressed on at least 40-50% of the cell lines. Our study while confirming 
the expression of NKG2D ligands on some standard cell lines [167-170] also 
demonstrates the pattern of NKG2D ligand expression on additional cell lines 
representing Hodgkin’s lymphoma, rhabdomyosarcoma and neuroblastoma. Just as in the 
case of NK susceptibility, no specific pattern of ligand expression was observed within 
cell lines of a particular cancer type. For example, although both T-ALL cell lines, 
expressed NKG2D ligands on their surface, 4 of 5 ligands were expressed on Jurkat while 
MOLT-4 showed the presence of only 2. In the MLL rearranged leukemic cell lines, 
while MV4-11 showed the presence of surface NKG2D ligands, RS4;11 and SEM had 
negligible expression. Thus expression of NKG2D ligands was seen to vary among 
tumors of the same histotype. Collectively, we observed differences in the number of 
ligands expressed, type of ligands expressed and intensity of expression as quantified by 
MFI in our cancer cell lines. These factors could be responsible for the differences in 
their NK susceptibility. 
 
 In order to correlate NK susceptibility and NKG2D ligand expression, we 
analyzed data using the K-means clustering algorithm. Spearman correlation coefficients 
between each ligand expression and corresponding percentage of cell lysis showed no 
particular ligand to have significant positive correlation with NK susceptibility i.e. there 
was no selective advantage in the expression of a specific NKG2D ligand (Table 3-1). In 
fact, the diversity in the NKG2D ligand family clearly argues in favor of no particular 
ligand being more potent or favorable than the other in inducing NK susceptibility. 
Various research groups have clearly shown that the expression of any NKG2D ligand 
sensitizes tumor cells to NK killing and there are no known features that distinguish 
NKG2D ligands with respect to their function [34, 62]. 
 
 Although NKG2D-mediated cytotoxicity of cancer cells is well known, the 
correlation between ligand expression and NK susceptibility has not been clearly 
established. The only paper addressing this was by Pende et al in 2002 where they 
reported that NKG2D mediated NK cytotoxicity strictly correlates with the expression 
levels and surface densities of its ligands on target cells [167]. However, their 
conclusions were based on qualitative analyses of ligand expression with NK 
cytotoxicity. For example, T cell lymphoma line H9 was characterized as ULBP2+ 
ULBP3+ and shown to have high NK susceptibility. In our study, we statistically 
analyzed the quantitative measure of NK lysis (in terms of % lysis) and NKG2D ligand 
expression (in terms of MFI) and performed a clustering algorithm to group our 
phenotypic observations. Cancer cells belonging to groups 1 and 2 showed that level of 
NKG2D ligand expression indeed correlates with NK susceptibility. However, our results 
also revealed a counterintuitive group 3 phenotype wherein cell lines exhibited NK 
resistance despite a high NKG2D ligand expression. This remarkable phenotype was seen 
in 25% of the cancer cell lines with no predominance of a particular cancer type. 
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Collectively, our results suggest that the level of NKG2D ligand expression usually (but 
not always) correlates with NK susceptibility of cancer. 
 
 Another striking observation was the absence of cancer cell lines representing a 
group 4 phenotype i.e. high NK susceptibility without the expression of NKG2D ligands. 
This was in accordance to our hypothesis that NKG2D is the primary pathway for tumor 
cell recognition. Because NKG2D-independent NK killing was not observed in our 
cancer cell spectrum, our data clearly indicated the importance of this pathway in cancer. 
Although NCR-dependent killing has been reported in various NKG2D ligand negative 
B-cell leukemic lines and neuroblastoma lines [157, 167, 171], it does not preclude the 
role of the NKG2D pathway in these cancers, provided these cell lines could also express 
NKG2D ligands with cell stress during transformation. 
 
 Furthermore, significant reduction in the lysis of the group 1 cancer cells by 
antibody blockade of NKG2D validated a substantial role of this pathway in NK 
susceptibility. Almost 80% reduction in NK lysis was observed in most of the group 1 
cells, clearly indicating that NKG2D was the primary pathway responsible for NK 
sensitivity of these cells. The observation of approximately 20-30 % lysis in the presence 
of the NKG2D antibody, however, suggests either incomplete blockade by the antibody 
or that other activating signals may simultaneously contribute to the NK susceptibility of 
these lines. Synergistic activating signals may be provided by NCRs or co receptors like 
DNAM-1 and 2B4 [172-174]. 
 
 
Lack of NKG2D Activation Is Commonly Responsible for NK Resistance 
 
 Analysis of blasts from patient samples showed that the majority of the patient 
samples exhibit the NK resistant group 2 phenotype. Only one patient exhibited the group 
1 phenotype with surface ULBP3 expression resulting in NK susceptibility. With strong 
evidence that cancer patients predominantly exhibit a group 2 phenotype, we created 
stable MICA expressing cell lines to determine whether the absence of NKG2D ligand 
expression was solely responsible for the NK resistance of our group 2 cancer cells. Our 
results indicate that transduction-mediated expression of MICA could increase the NK 
susceptibility of these resistant cell lines. This effect was not specific to a particular 
cancer type as similar observations were made in cell lines representing leukemia, 
lymphoma and neuroblastoma (Figure 4-5). Moreover, the dependency on the NKG2D 
pathway was validated by using the NKL cell line as effectors. NKL expresses high 
levels of NKG2D, but only minimal levels of NCRs and is therefore well suited to study 
NKG2D-mediated recognition [34]. 
 
 In light of the above observations we focused our understanding on mechanisms 
employed by group 2 cancer cells to prevent surface expression of NKG2D ligands and 
designing strategies to overcome the repression of expression. Our results show that the 
majority of group 2 cancer cells express MICA mRNA. However, comparison of their 
mRNA levels with that of the group 1 cell line K562 revealed considerably lower level of 
MICA transcripts in all group 2 cell lines. In particular, no detectable mRNA was seen in 
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the neuroblastoma lines. These results indicated transcription repression of MICA in the 
group 2 cancer cells. To further probe into the mechanisms of gene silencing, we 
determined whether histone acetylation was responsible for the low mRNA levels. 
Chromatin remodeling through histone acetylation has been implicated in the 
transcriptional control of genes [175]. Valproic acid has been shown to relieve HDAC-
dependent transcriptional repression by causing hyperacetylation of histones in cultured 
cells and in vivo [176]. Our findings clearly demonstrate that HDAC inhibitor sodium 
valproate induced MICA mRNA and protein in the group 2 cancer cells albeit at variable 
levels. 
 
 The neuroblastoma lines including NB-1691 and CHLA-255 showed a marked 
increase in MICA mRNA and protein after treatment with HDACi sodium valproate. 
Expression of surface MICA resulted in an augmented lysis by NK cells which was 
completely abolished by the NKG2D blocking antibody, thus validating the role of this 
pathway. Downregulation of NKG2D ligands in neuroblastoma lines and patients has 
been reported previously [167, 172, 177] but to our knowledge histone acetylation has 
never been implicated for the lack of surface expression of NKG2D ligands in 
neuroblastoma. Shedding of MICA has been associated with the lack of surface 
expression in neuroblastoma lines [177]. In our study we ruled out this possibility 
because soluble MICA was not detected in cell culture supernatants. Our study provides 
the first evidence of transcriptional repression of NKG2D ligands in neuroblastoma lines. 
In addition to MICA, other NKG2D ligands were also increased at the mRNA and 
surface protein levels in the neuroblastoma cell lines after treatment with HDACi sodium 
valproate (Figure A-1). Although it is well known that NK lysis of neuroblastoma cells 
may be mediated via the NCR and DNAM-1 pathways [157, 171, 178], our study 
presents an alternative pathway that is clinically feasible to increase NK susceptibility of 
these resistant tumors. 
 
 For the group 2 cell lines representing leukemia or lymphoma, treatment with 
sodium valproate resulted in marginal upregulation of MICA mRNA. This was mirrored 
by a minimal increase in MICA on the surface of these cells and marginal increase in NK 
susceptibility suggesting that MICA expression in these lines could only partially be 
rescued by histone acetylation. Possibly additional post transcriptional/ post translational 
mechanisms may be involved in the regulation of MICA. Importantly, although MICA 
expression was only marginally upregulated by sodium valproate, the NKG2D ligand 
ULBP2 was induced considerably at the mRNA and surface protein levels in majority of 
the group 2 cancer cells (Figure A-2). Similarly, studies have reported induction of 
different NKG2D ligands combined with varying degrees of induction when treated with 
HDAC inhibitors [179]. Armeanu et al reported that sodium valproate increases 
transcription of MICA/B without affecting ULBPs in hepatoma cells [107]. Diermayr et 
al, showed the upregulation of ULBP1 and MICA/B on primary AML cells [180] while 
Poggi et al reported the induction of MICA, ULBP2 and ULBP3 on primary AML cells 
by sodium valproate [181]. Lopez-Soto et al reported trichostatin A induces ULBPs but 
not MICs in epithelial cancer cells. This heterogeneity suggests that diverse molecular 
mechanisms are involved in the HDACi effect on the expression of different NKG2D 
ligands. Similarly, our results show that HDACi sodium valproate increases MICA 
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mRNA and surface protein with different reaction patterns in the investigated group 2 
cell lines.  
 
 To investigate other mechanisms that might be responsible for the absence of 
surface MICA in the NK resistant leukemia and lymphoma group 2 cell lines, proteolytic 
shedding of MICA was explored [86]. Remarkably, under our experimental conditions, 
soluble MICA was not detected in the cell culture supernatants suggesting that an 
alternate mechanism was responsible for the absence of surface MICA. Intracellular 
sequestration of MICA was thus examined. By immunofluorescence microscopy, 
intracellular MICA was observed in the group 2 cells but in comparison to the group 1 
cell line K562, the levels were considerably lower. In the group 1 cells, both surface and 
intracellular MICA was observed while in the group 2 cells it was only seen 
intracellularly. The low level of MICA protein was in accordance with the low levels of 
mRNA seen in these group 2 cell lines. Next, investigation of the subcellular localization 
of MICA by colocalisation markers and confocal microscopy demonstrated substantial 
co-localization of MICA with the ER marker calnexin in the group 2 cells and also an 
AML patient that lacked surface MICA. We could not detect co-localisation of MICA 
with markers for the golgi complex, endosomes or lysosomes. Intracellular retention of 
NKG2D ligands in the ER and cis-Golgi has been reported previously in the context of 
human CMV infection of fibroblasts [103, 105, 182, 183] but similar phenomenon is not 
well established in tumor cells. Our studies demonstrate intracellular sequestration of 
MICA in leukemia and lymphoma cells similar to observations made previously in 
melanoma [83]. 
 
 Retention of MICA in the ER could be due to association to chaperones, presence 
of ER retention or retrieval sequences such as KDEL or KEDL, post translational 
modifications induced by ER quality control mechanisms such as unfolded protein 
response and ER associated degradation [184-188]. In fact, it was recently reported that 
tumor cell-associated carcinoembryonic antigen (CEA)-related cell adhesion molecule 1 
(CEACAM1) causes intracellular retention of MICA/B in human tumor cells [189]. Also, 
MICA associates with specific chaperones such as ERp5 that cause cleavage of this 
ligand from cell surface of tumor cells [92]. Further studies are warranted to determine 
whether an association with these proteins is responsible for absence of surface MICA in 
the group 2 cells. 
 
 Aberrations in the proteasome system have been associated with a number of 
diseases including cancer [190]. Proteasome inhibitors such as bortezomib, have been 
licensed for therapy of multiple myeloma and are currently in trails to assess its efficacy 
for treatment of other malignancies [191]. Hence, to rescue the intracellularly retained 
MICA in our group 2 cell lines, proteasome inhibitor bortezomib was applied to the 
tumor cells. An increase in intracellular MICA was observed not only in group 2 cells but 
also group 1 cancer cells post treatment with Bortezomib. This suggested that 
proteasomal degradation of MICA was a normal physiological process and inhibiting this 
by bortezomib may be a simple therapeutic strategy to increase MICA protein. The 
increase in intracellular MICA protein resulted in augmented expression of MICA on the 
surface of cancer cells. Subsequently, we determined the functional significance of the 
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enhanced MICA surface expression on the group 2 cancer cells. An increased NK 
susceptibility was observed and the role of the NKG2D pathway was confirmed by anti-
NKG2D blocking antibody which resulted in a significant abrogation of NK lysis of the 
treated cells. 
 
 Various groups have published conflicting data on induction of NKG2D ligand 
mRNA by bortezomib. Butler et al reported that bortezomib up-regulated ULBP1 mRNA 
but not that of the other ligands [170]. Gomez et al reported an increase in ULBP2 
mRNA but not MICA/B [169] while Armeanu et al reported that MICA/B mRNA was 
up-regulated in response to Bortezomib [192]. The discrepancy in their findings may be 
due to different cell lines used in their studies. In our study, MICA mRNA was not 
significantly up-regulated after bortezomib treatment in the group 2 cancer cell lines 
(Figure A-3) suggesting that the increase in MICA protein was not due to an increased 
transcription of the gene. Furthermore, bortezomib has been previously shown to enhance 
NK lysis of primary tumors by downregulating surface expression of the inhibitory MHC 
class I molecules in myeloma cells [193]. However in our study, analysis of bortezomib 
treated primary leukemic patient blasts showed no significant change in the surface 
expression of HLA molecules (Figure A-4). Thus, our preliminary observations argue 
against downregulation of MHC class I after bortezomib treatment in agreement with 
data by Lundqvist et al [194].  
 
 Taken together, our data conclusively show that the absence of surface expression 
of MICA on the group 2 cells was due to regulation at transcriptional and post 
translational levels. Transcriptional repression resulting in low mRNA levels was the 
foremost mechanism for the absence of MICA on the surface. Although marginal levels 
of protein were observed in some cell lines, intracellular retention in the ER provided a 
secondary escape route. Treatment with clinically relevant modulators like HDACi 
sodium valproate and proteasome inhibitor bortezomib were able to increase MICA at the 
mRNA and/or protein levels, enhanced its surface expression and overcame NK 
resistance in the majority of cancer cell lines.  
 
 Various reports suggest that ligands are regulated somewhat differently by stress 
pathways and that different cellular stresses selectively trigger upregulation of expression 
of different sets of NKG2D ligands. This feature presumably allows the same receptor to 
stimulate a response in different contexts because of upregulation of distinct ligands. 
Although our study used MICA as a model to investigate the mechanism of NK 
resistance in the group 2 cell lines, other NKG2D ligands are also under transcriptional, 
post transcriptional or translational regulation and they respond differently to different 
cellular stresses. From our observations and others, transcriptional repression of MICB 
and ULBP genes was also observed. ULBP2 mRNA and surface expression was 
significantly upregulated by HDACi treatment while histone acetylation could only 
partially rescue MICB and ULBP1 (Figures A-2, A-5 and A-6). The differential effect of 
HDACi on the regulation of NKG2D ligands clearly suggests that additional mechanisms 
of downregulation may be involved in the regulation of MICB and ULBP1. In fact, Tang 
KF et al showed that DNA methyltransferase inhibitor 5-azacytidine could upregulate 
MICB by promoting DNA methylation [195]. Furthermore, results from our study on 
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MICA elucidate the possibility of a similar subcellular retention of other NKG2D ligands 
particularly MICB and ULBP1 in cancer cells. Further studies are warranted to test these 
hypotheses. 
 
 
NKG2D Ligand Expression Does Not Necessarily Lead to NK Activation  
 
 In contrast to the group 1 and group 2 cells, the group 3 cancer cells had an 
intriguing phenotype of NK resistance despite a high NKG2D ligand expression. This 
novel phenotype, although seen in only 25% of our cancer cell lines, suggests the 
existence of mechanisms that can override NKG2D activation. In an effort to uncover the 
NK resistance mechanisms in group 3 cell lines, we determined whether intrinsic features 
such as PI-9 expression were responsible. It has been shown in mice and in several 
cancers that overexpression of PI-9 directly protects cells from apoptosis through 
granzyme B inhibition [155, 196, 197]. However, our data revealed no significant 
difference in the levels of PI-9 between the resistant group 3 cell lines and the NK 
susceptible group 1 cells, suggesting the role of other factors in conferring NK resistance. 
 
 Several studies have demonstrated that the cell surface expression of NKG2D 
ligands results in an increased susceptibility of MHC class I expressing tumors to NK 
cells, thereby suggesting that NKG2D mediated cytotoxicity can override KIR inhibitory 
signaling [26, 27, 34]. However, contrasting studies showed that engagement of 
inhibitory receptors was able to efficiently block NKG2D-mediated cytotoxicity [44, 
198]. In our studies, group 1 cells with high NKG2D ligand expression and high NK 
susceptibility illustrated the former observation where NKG2D-mediated cytotoxicity 
was able to overcome inhibitory signaling. However, in the group 3 cells that were NK 
resistant despite a high NKG2D ligand expression, blockade of inhibitory MHC class I 
molecules resulted in an increased NK susceptibility suggesting that strong inhibitory 
signaling through KIR could override NKG2D activation in these cancers. This was in 
agreement with the observations of Pende et al [44], but in contrast to their data that was 
based solely on redirected killing assays, our results provide direct evidence on how 
tumor cells may evade NKG2D-mediated cytotoxicity in the natural setting. We also 
show that the increased NK lysis of the group 3 cancer cells after HLA blockade was 
driven by the NKG2D pathway since blockade of NKG2D resulted in a marked reduction 
in NK lysis. This observation further substantiates the role of the NKG2D pathway in 
conferring NK susceptibility to cancer cells. Interestingly, HLA blockade on group 1 
cancer cells (high NKG2D ligand expression) did not further increase the NK 
susceptibility of these cell lines (Figure A-7). 
 
 Taken together, HLA blockade experiments with the group 1 and 3 cell lines 
clearly demonstrate the ‘dynamic equilibrium’ concept that regulates NK function. 
According to this model, NK cytotoxicity is regulated by a fine balance between 
activating and inhibitory signals such that if the balance tips towards inhibition, NK lysis 
will be inhibited and vice versa. The NK resistant group 3 cells represent the net balance 
tipped towards inhibition. However, when the balance is tipped towards activation by 
MHC blockade, they become susceptible to NK killing. In contrast, group 1 cells are 
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representative of the net balance tipped towards activation and hence their high NK 
susceptibility. Moreover, since the net activation has already exceeded the net inhibition 
in these cells, MHC blockade does not further augment their NK sensitivity. Although, 
mean NKG2D ligand expression scores for the group1 and 3 cell lines were comparable, 
the discrepancies in their NK susceptibility post HLA blockade can be speculated to be 
due to differences in the expression of other activating ligands that may provide a 
synergistic activating signal to NKG2D activation. These include (but are not limited to) 
NCR ligands, ligands for other NK co-receptors and also the NKG2D ligands ULBP 4, 5 
and 6 that were not included in our study due to lack of specific antibodies and reagents 
[44, 199, 200]. Another possibility for the differences observed between group 3 and 
group 1 cell lines may be the strength of the negative signal [201, 202] as unpublished 
data from ongoing studies in our lab demonstrates variable strength of inhibition by 
different HLA alleles. 
 
 Nevertheless, HLA blockade on the group 2 cells (lack NKG2D ligands) showed 
no increase in NK lysis of these cells, suggesting that the release of inhibition alone is not 
sufficient for NK lysis of tumors [24] (Figure A-8). An example of this situation may be 
represented by encounters between human erythrocytes and circulating peripheral blood 
NK cells. Although human red blood cells do not express the inhibitory MHC class I, NK 
cells do not attack them because erythrocytes lack ligands capable of engaging the 
activating NK cell receptors [24]. In our study, when MICA was ectopically expressed in 
the group 2 cancer cell lines, they were efficiently lysed by NK cells clearly illustrating 
that rather than the mere absence of inhibition, the presence of activation is absolutely 
required for NK lysis (Figure 4-5). This phenomenon is also clearly demonstrated by two 
MHC class I negative cancer cell lines K562 and Daudi. While both cell lines lack 
inhibitory ligands, K562 (group 1) is efficiently lysed by NK cells due to the presence of 
NKG2D activation ligands but Daudi (group 2) is NK resistant due to the absence of 
activating ligands. 
 
 Although NK resistance due to KIR inhibition overriding NKG2D activation was 
common among the group 3 cell lines, rhabdomyosarcoma line RD was an exception. 
Since the RD cells did not show increased NK lysis post treatment with HLA class I 
blockade, its ability to activate NK cells was evidently limited. The inability of RD cells 
to degranulate NK cells suggests the incapability of these cells to adhere to NK cells. 
Conjugate formation between NK cells and its targets is a prerequisite for NK cell 
activation and cytotoxicity [203]. Since strong adhesion to target cells mediated by the 
adhesion receptor-ligand pair of LFA-1 and ICAM-1 is required for lysis by NK cells 
[204, 205], we determined ICAM-1 levels on all group 3 cell lines and found low surface 
expression of ICAM-1 specifically on RD. It can be speculated that the low levels of 
ICAM-1 impairs NK:target conjugate formation resulting in NK resistance in this cell 
line. However, assays to enumerate formally the effector:target conjugates will be 
necessary to confirm this hypothesis. The low levels of ICAM-1 on RD cells may be due 
to shedding of this molecule as shown in several cancers [206-208] or micro RNA 
mediated repression [209].  
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Translational Significance of Our Findings 
 
 In the past 15 years many groups have reported the anti-cancer effects of NK cells 
in humans [114, 210-212]. Strong evidence of the clinical benefits of NK cells was 
provided by Imai K et al in 2000 wherein their prospective study of 3625 healthy adults 
in Japan with a median followup of 11 years, showed that individuals who had higher 
than baseline NK cytotoxicity of K562 cells were at a significantly lower risk of 
developing adult cancers [112]. A number of clinical trials with infusion of allogeneic 
NK cells in patients with malignant diseases have shown feasibility with no side effects 
[213]. Ruggeri et al [114, 214] and others [158, 215] have shown that allogeneic NK cells 
can mediate antileukemic effects against AML. However, in a study by Miller et al, only 
5 of the 19 AML patients obtained remission after NK transplantation, [216]. Moreover, 
all the renal cancer patients in their study did not show a favorable response [216]. 
Similarly, another study involving 20 patients with recurrent ovarian or breast cancer 
showed that NK infusions were well tolerated but no tumor responses were observed 
[124]. Several protocols of clinical-grade NK cell purification and in vitro population 
expansion are now validated, and studies have shown that the infusion of allogeneic NK 
cells is safe in humans [118, 122, 123] but the efficacy of NK cell based tumor therapies 
has not yet been firmly established. Although the results of NK based immunotherapeutic 
treatments of cancer are promising in the experimental models, till date their clinical 
efficacy in human trials has been modest, presumably due to tumor escape by alteration 
of NK cell function and resistance to NK killing [217-221].  
 
 Our comprehensive study on hematological malignancies and solid tumors 
provides fundamental insights concerning the biological mechanisms responsible for the 
modest clinical efficacies of NK cell therapy. Specifically, we determined the prevalence 
of NK susceptibility in a wide spectrum of cancer cell lines representing various cancer 
types. Our observations of NK resistance in the cancer cell lines was further validated by 
leukemia patient samples that exhibited 90% NK resistance. Correlation studies on 
NKG2D ligand expression and NK cytotoxicity resulted in the observation of 3 
phenotypic clusters suggesting that the level of NKG2D ligand expression usually (but 
not always) correlates with NK susceptibility. On applying our cell line findings to 
patient samples, we observed the group 2 phenotype to be predominant in pediatric 
leukemia. Furthermore, induction of NKG2D ligands by HDACi sodium valproate or 
proteasome inhibitor bortezomib was conducted on primary patient blasts from an MLL 
patient who exhibited a group 2 phenotype with absence of ligands and NK resistance. 
The increase in surface MICA and ULBP2 resulting in an increased NK cell 
degranulation and augmented NK sensitivity substantiated our findings from the group 2 
cancer cell lines. Also, blockade of the inhibitory HLA-KIR interaction on AML blasts 
from a representative group 3 patient demonstrated a significant increase in the NK 
sensitivity of the patient blasts thereby confirming our group 3 cell line findings. Role of 
the NKG2D pathway in conferring NK susceptibility was established by NKG2D 
neutralizing antibodies that abrogated NK lysis of the blasts in both the group 2 and 
group 3 type patients. Taken together, results from our patient samples mirror our 
clustering model and suggest that NKG2D pathway can be modulated clinically. 
However, one caveat of our patient data is the inclusion of leukemia samples only. Based 
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on the limited clinical effectiveness observed in adoptive NK therapy of solid tumors till 
date [124, 222], we speculate similar results on NK resistance and NKG2D pathway 
modulation in primary solid tumor samples as well.  
 
 Additionally, our clustering plot can be used as a predictive model to determine 
the clinical efficacy of NK transplantation in patients (Figure 5-1). Hypothetically, by 
analyzing 2 parameters including NK susceptibility and NKG2D ligand expression, we 
can determine the likelihood of patient responses to NK cell therapy by grouping them 
into phenotypic clusters. For example, if analysis shows the patient blasts to express high 
surface NKG2D ligands and high NK susceptibility indicative of the group 1 phenotype, 
such a patient would represent an ideal candidate for NK cell therapy. Alternatively, if 
the patient shows a low NKG2D ligand expression and NK resistance indicative of the 
group 2 phenotype, NKG2D ligands would need to be induced to make this patient’s cells 
susceptible to NK lysis. In order to make NK therapy a success in this patient, the 
NKG2D ligands would have to be modulated using agents such as HDACi sodium 
valproate and/or proteasome inhibitor bortezomib, thereby transforming this patient to a 
group 1 phenotype. 
 
 Furthermore, if analysis predicts a patient having the group 3 phenotype, blockade 
of KIR inhibitory signaling would be beneficial to improve NK susceptibility. In fact, a 
therapeutic KIR blocking antibody is currently in clinical trials for AML and multiple 
myeloma [219]. This monoclonal antibody 1-7F9, recognizes KIR2DL1, 2, and 3 and 
therefore blocks the inhibition imposed by virtually all MHC class I C alleles, allowing it 
to be tested in all patients irrespective of their KIR and HLA genotypes [223]. If this 
antibody proves successful in clinical trials, it would benefit our group 3 patients 
undergoing NK transplantation. Moreover, KIR inhibitory antibody may also be used in 
combination with NKG2D ligand inducers such as sodium valproate for further 
augmenting NK responses via the NKG2D pathway in group 2 cancer cells [104]. 
 
 Our study conclusively shows that the NKG2D pathway can be manipulated to 
overcome NK resistance thereby improving the immunotherapeutic potential of NK cell 
therapy. Modulating this pathway can prove beneficial when used singly or as part of a 
multipronged approach to augment the function of NK cells, including the use of 
cytokine [224], 4-1BB ligand [140], chimeric antigen receptors [225] and KIR antibody 
[223]. Several groups have conducted in vitro and in vivo studies on immune cells 
transduced with NKG2D-CAR [146, 150, 225, 226]. The success of such 
immunotherapeutic strategies relies heavily on the presence of NKG2D ligands on the 
cancer cells. While group 1 and group 3 type cancer cells would be susceptible to lysis by 
these CAR expressing cells, the group 2 cells being ligand negative would be resistant. 
However, HDACi and/ bortezomib treatment may be applied prior to adoptive transfer of 
the NKG2D-CAR bearing cells to ensure clinical efficacy of such therapeutic strategies 
[225]. It has been reported that ex vivo expanded NK cells kill NK resistant 
neuroblastoma cell lines through the NCR and DNAM-I pathways [157]. Although 
effective tumor lysis was observed in this study, we propose that HDACi mediated 
NKG2D ligand induction on neuroblastoma lines may present an alternate and clinically  
 62 
 
 
Figure 5-1. Model for determining strategies for NK therapy. 
Cluster plot demonstrating the possible outcomes of NK therapy based on NKG2D ligand 
expression and NK susceptibility. 
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expedient pathway to enhance tumor lysis. This may be particularly beneficial in donors 
that are represented by an NCR dull phenotype since NKG2D receptor is constitutively 
and homogenously expressed. In conclusion, the clinical potential of NK immunotherapy 
can be enhanced by modulation of the NKG2D pathway. In accordance to the findings of 
this study, research in our lab is currently focused on high throughput screening (HTS) 
strategies to identify clinically safe drugs capable of modulating the NKG2D pathway. 
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CHAPTER 6.    CONCLUSION 
 
 
 Surgery, chemotherapy and ionizing radiation have been used for decades as 
primary treatments for cancers. However, the development of resistance to these 
approaches has led to significant incidence of tumor relapse. Immunotherapy for cancer 
has thus drawn interest given its non-overlapping toxicity with chemotherapy and 
radiation therapy and an apparent lack of long term toxicity. In particular, the clinical 
potential of the innate immune cells namely NK cells has been harnessed in the treatment 
of cancers because they are very good candidates for immunotherapy. NK cells 
demonstrate rapid response (cytotoxic in minutes without prior sensitization, high 
potency (tumoricidal rather than tumoristatic), broad specificity (easily differentiate 
normal cells from tumor cells but do not require different preparations for different tumor 
types), potential for optimal donor selection (lab assays), ease of preparation and 
administration, lack of side effects (no GVHD and organ toxicity) and complementarity 
to other therapeutic strategies (can be administered alongwith antibodies, cytokines, bone 
marrow transplantation or gene therapy) [160]. These exceptional qualities have led to 
the use of NK transplantation for treatment of hematological malignancies and solid 
tumors. However, observation of modest clinical efficacy underscores the need for a 
better understanding of the factors that undermine NK therapy. 
 
 In an effort to understand some of the reasons that hinder the beneficial effects of 
NK cellular therapies, our study comprehensively analyzed a spectrum of 20 cancer cell 
lines representing various different cancer types. Analysis of their NK susceptibility 
showed NK resistance to be prevalent. Since NKG2D is a major activating receptor on 
NK cells, we characterized the role of this pathway in cancer. Heterogeneity in NKG2D 
ligand expression was observed among the cancer cells. Correlation between NKG2D 
ligand expression and NK susceptibility led to the observation of group 1 cells (high 
NKG2D ligand expression, high NK susceptibility), group 2 cells (low ligand expression, 
low NK susceptibility), group 3 cells (high ligand expression, low NK susceptibility) 
thereby suggesting that ligand expression does not always correlate with NK 
susceptibility. Ectopic expression of MICA overcame NK resistance in the group 2 
cancer cells suggesting that absence of surface NKG2D ligands was responsible for NK 
resistance. Further investigations of resistance mechanisms in the group 2 cancer cells led 
to the observations that they lacked surface expression of NKG2D ligands due to low 
mRNA and /or protein levels. Transcriptional repression was primarily responsible for 
absence of surface ligands. In cells that expressed some protein, ER retention of NKG2D 
ligands (particularly MICA) contributed to an additional NK evasion mechanism. 
However, treatment with HDACi sodium valproate or proteasome inhibitor bortezomib 
helped circumvent these regulatory mechanisms resulting in increased expression of 
NKG2D ligands and NK susceptibility. While the lack of NKG2D activation was 
responsible for the NK resistance of the group 2 cancer cells, NK resistance of group 3 
cancer cells was due to inhibitory signals overriding NKG2D activation. Blockade of the 
inhibitory KIR-HLA interaction significantly augmented NK lysis in these cells.  
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 Finally, analysis of fresh leukemia patient samples validated our phenotypic 
clusters and cell line findings. Taken together, our study conclusively shows that NKG2D 
evasion mechanisms are strongly prevalent in cancer; however the NKG2D pathway is 
amenable to therapeutic alteration. By using our clustering plot as a predictive model to 
determine the efficacy of NK therapy and by implementing therapeutic strategies to 
modulate this pathway, greater clinical benefit will be expected for NKG2D-mediated 
NK immunotherapy. Thus, NK transplantation holds considerable promise for future NK 
cell therapies in cancer. 
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APPENDIX. SUPPLEMENTARY FIGURES FOR CHAPTER 5 
 
 
 
 
 
 
Figure A-1. Histone deacetylase inhibitor sodium valproate upregulates mRNA 
and protein levels of other NKG2D ligands in neuroblastoma. 
(A) Relative MICB, ULBP1 and ULBP2 mRNA levels in untreated (white) and 5mM 
treated NB-1691(black) four days after treatment. (B) Histograms of surface MICB, 
ULBP1 and ULBP2 on untreated (black) and sodium valproate treated (red) 
neuroblastoma cells. Isotype control was presented as shaded histograms. Data are 
representative of 3 experiments. 
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Figure A-2. Histone deacetylase inhibitor sodium valproate significantly 
upregulated ULBP2 mRNA and protein expression on group 2 leukemia and 
lymphoma cell lines. 
(A) Relative ULBP2 mRNA levels in untreated (white) and sodium valproate treated 
(black) group 2 cancer cells. (B) Histograms of ULBP2 surface expression on untreated 
cells (black line) and sodium valproate treated cells (red line) 48 hours after treatment. 
Isotype control was presented as shaded histogram. Data are representative of 3 
independent experiments. 
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Figure A-3. Bortezomib does not increase MICA mRNA. 
Relative MICA mRNA levels in untreated (white) and bortezomib treated (black) group 2 
cancer cells. 
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Figure A-4. Bortezomib does not downregulate HLA-ABC in patient cells. 
Histograms of HLA-ABC surface expression on untreated cells (black line) and 
bortezomib treated cells (red line) in the indicated patient samples. Isotype control was 
presented as shaded histogram. 
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Figure A-5. Histone deacetylase inhibitor treatment marginally upregulated 
MICB mRNA and surface protein in the group 2 leukemia and lymphoma cell lines. 
(A) Relative MICB mRNA levels in untreated (white) and sodium valproate treated 
(black) group 2 cancer cells. (B) Histograms of MICB surface expression on untreated 
cells (black line) and sodium valproate treated cells (red line) 48 hours after treatment. 
Isotype control was presented as shaded histogram. Data are representative of 3 
independent experiments. 
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Figure A-6. Histone deacetylase inhibitor treatment marginally upregulated 
ULBP1 mRNA and surface protein in the group 2 leukemia and lymphoma cell 
lines. 
(A) Relative ULBP1 mRNA levels in untreated (white) and sodium valproate treated  
(black) group 2 cancer cells. (B) Histograms of ULBP1 surface expression on untreated 
cells (black line) and sodium valproate treated cells (red line) 48 hours after treatment. 
Isotype control was presented as shaded histogram. Data are representative of 3 
independent experiments.  
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Figure A-7. HLA inhibition does not further increase NK susceptibility of group 1 
cells. 
(A) Expression of inhibitory ligands HLA-ABC (black line) on the indicated group 1 cell 
lines. Isotype control was presented as shaded histogram. Data are representative of 2 
independent experiments. (B) NK susceptibility of group 1 cell lines untreated (blue line), 
treated with anti- HLA-ABC blocking antibody (red line), treated with anti-NKG2D 
antibody (purple line), treated with anti-HLA blocking antibody+anti-NKG2D blocking 
antibody (green line) to NK cells at E:T ratios 5:1, 10:1, 20:1. Data are mean % lysis ± 
SEM from 3 independent experiments.  
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Figure A-8. HLA inhibition does not increase NK susceptibility of group 2 cancer 
cells. 
(A) Expression of inhibitory ligands HLA-ABC (black line) on the indicated group 2 cell 
lines. Isotype control was presented as shaded histogram. Data are representative of 2 
independent experiments. (B) NK susceptibility of group 2 cell lines untreated (blue line), 
treated with anti- HLA-ABC blocking antibody (red line), treated with anti-HLA 
blocking antibody+anti-NKG2D blocking antibody (green line) to NK cells at E:T ratios 
5:1, 10:1, 20:1. Data are mean % lysis ± SEM from 3 independent experiments. 
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